

CHEMICAL PRODUCTS CORPORATION  
CARTERSVILLE, GEORGIA 30120

POST OFFICE BOX 2470

TELEPHONE 770-382-2144  
FAX 770-386-6053

October 29, 2018

via Electronic Mail (quality.guidelines@epa.gov)

*Information Quality Guidelines Staff*

Mail Code 28221T

U.S. EPA

1200 Pennsylvania Ave. N.W.

Washington, DC, 20460

Subject: Request for Reconsideration of RFC #18001

Dear Madam or Sir;

Chemical Products Corporation (CPC) is dissatisfied with EPA's decision regarding Request for Correction #18001 (RFC #18001). This letter constitutes CPC's Request for Reconsideration (RFR) of RFC #18001. CPC's technical director wishes to be present when this RFR is presented to EPA's expert panel.

RFC #18001 was submitted on April 6, 2018 and additional information was submitted on April 20, 2018; EPA's decision is dated September 21, 2018. RFC #18001 is included with this letter as "RFR Attachment 1" and EPA's September 21, 2018 response (including its two attachments) is included with this letter as "RFR Attachment 2".

CPC disagrees with EPA's response because EPA did not objectively evaluate the documentation provided with RFC #18001 which demonstrates that National Toxicology Program (NTP) Technical Report 494 (TR494) on 9,10-Anthraquinone (AQ) does not represent sound science. The 9,10-AQ PPRTV is based on the TR494 studies. The 9,10-PPRTV resulted in inclusion of 9,10-AQ in EPA's RSL tables.

CPC again requests that EPA withdraw the 9,10-AQ PPRTV and remove 9,10-AQ from the RSL Tables because there is no scientifically valid justification for inclusion of 9,10-AQ in the RSL Tables.

AQ is not mutagenic, but the TR494 studies were unknowingly conducted with a test article which was contaminated with the potent mutagen, 9-nitroanthracene. A draft TR494 (containing the same conclusions found in the published TR494) was peer reviewed in 1999 before the 9-nitroanthracene contamination had been detected. No bioassay of the TR494 test article, Lot 5893, had been conducted at that time.

Contamination by the potent mutagen 9-nitroanthracene was discovered in the TR494 test article after peer reviewers had approved the conclusions in the 1999 draft TR494; NTP was notified.

Quantification of 9-nitroanthracene contamination and a positive mutagenicity assay of the NTP TR494 test article, Lot 5893, was reported in 2001 (The preparation of anthraquinone used in the National Toxicology Program cancer bioassay was contaminated with the mutagen 9-nitroanthracene; Butterworth, Mathre, and Ballinger; Mutagenesis vol. 16 no.2; pp. 169-177; 2001).

A scientific analysis of the TR494 studies was conducted by NIEHS/NTP Deputy Director Samuel H. Wilson in 2003. At that time he was also head of the DNA Repair and Nucleic Acid Enzymology Section in the NIEHS/NIH Laboratory of Structural Biology, a position he still occupies (he also holds a secondary appointment in the NIEHS

Epigenetics and Stem Cell Biology Laboratory). Deputy Director Wilson stated:

“...I have reached the following conclusions:

1. The sample of anthraquinone used in the NTP 2-year study was contaminated with 9-nitroanthracene at a level of about 0.1%.
2. The presence of this contaminant raises doubt as to the effect(s) of anthraquinone itself, or its metabolites, and confounds interpretation of the NTP studies referenced in draft TR-494....”

Dr. Wilson’s conclusions were contained in his September 8, 2003 response to CPC’s March 27, 2003 RFR; at that time he withdrew the draft TR494 peer reviewed in 1999, and committed to revisions of TR494 and another peer review. Dr. Wilson’s letter was included in the supplemental information provided with RFC #18001 and is included again as “RFR Attachment 3”.

In 2004 NTP commissioned BioReliance to perform a bioassay of sample “A07496”; it was found to be non-mutagenic. Sample “A07496” was presented to peer reviewers as an aliquot of the TR494 test article, Lot 5893; the absence of mutagenicity in “A07496” was employed to contradict the positive mutagenicity reported in 2001 and demonstrate that mutagenic contamination in the TR494 test article was not biologically significant.

Peer reviewers accepted the negative mutagenicity of sample “A07496”, presented as an aliquot of Lot 5893, as sufficient to eliminate mutagenic contamination as a confounding factor in the interpretation of the TR494 studies.

CPC obtained the sample shipment records from Battelle, the sole repository for TR494 test article, Lot 5893, and found that no shipments of AQ were shown in the sample shipment records for the period in question. CPC submitted a RFC to NIEHS/HHS seeking removal of sample "A07496" data from TR494 followed by peer review of the revised TR494. NTP subsequently provided an "inadvertent omission", a Bulk Chemical Shipment Report sheet showing shipment of a sample labeled "Lot 5893" from Battelle to BioReliance on June 1, 2004.

The BioReliance Test Article Receipt and Transfer Report (BTL Test Article Report), provided with RFC #18001, was eventually obtained by appealing the denial of CPC's FOIA request. The BTL Test Article Report shows that a sample labeled "A07496" was received by BioReliance on June 2, 2004; a note states that the sample was not logged in until June 4, 2004 because the Sponsor Site in the Oracle Module was inactive.

Under no conceivable circumstance could the sample received by BioReliance on June 2, 2004 labeled "A07496" be a sample sent from Battelle on June 1, 2004 labeled "Lot 5893".

The BTL Test Article Report showing that BioReliance received a sample labeled "A07496" on June 2, 2004 was provided to NIEHS/HHS in CPC's 2007 RFR. Nonetheless, NIEHS/HHS asserted in its 2008 denial of CPC's RFR that sample "A07496" was an aliquot of "Lot 5893"; NIEHS/HHS asserted that "BioReliance confirmed assignment of each test article aliquot number to the correct lot of anthraquinone."

The BTL Test Article Report provides unambiguous proof that BioReliance did not assign a test article aliquot number to a sample received as "Lot 5893". BioReliance maintained the sample designation which was attached to the sample when BioReliance received it.

The blatant fiction advanced by NIEHS/HHS in 2008 that BioReliance confirmed that sample "A07496" was an aliquot of "Lot 5893" has been accepted by EPA and repeated in its response to RFC #18001. CPC hopes that EPA's expert panel will correct this glaring error in EPA's response, and recognize the assertion that the TR494 test article was not mutagenic as untenable.

An independent analysis of the conclusions in TR494 was published in 2009. A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards states on page 719, "The data for anthraquinone are considered suspect because other carcinogenicity studies were negative, and the NTP carcinogenicity study used a batch of anthraquinone contaminated with the potent mutagen 9-nitroanthracene at a level of 1,200 ppm (Butterworth, Mathre, and Ballinger 2001). (A purified sample was negative in the Ames test.) Certainly, it can be said that the material used by the NTP was mutagenic...." [Toxicologic Pathology, 37: 714-732, 2009]. One of the authors of this paper was Douglas C. Wolf of the U.S. Environmental Protection Agency, Research Triangle Park. This paper was included in the supplemental information provided with RFC #18001 and is a part of RFR Attachment 1.

The contact for this RFR is CPC's technical director, Jerry A. Cook.  
His contact information is:

email: [jcook@cpc-us.com](mailto:jcook@cpc-us.com)

phone: 770-382-2144 Ext.272

cell phone: 770-714-3806

mailing address: Mr. Jerry A. Cook

Chemical Products Corporation  
102 Old Mill Road, SE  
P.O. Box 2470  
Cartersville, GA 30120

CPC's technical director, Jerry Cook, wishes to attend the RFR presentation to EPA's expert panel. He also wishes to make a presentation to EPA's expert panel at that time. Additionally, he hopes to invite the Chief of Staff for Congressman Barry Loudermilk, Rob Adkerson, to attend the RFR presentation to EPA's expert panel.

#### In Summary

1. EPA's response to RFC #18001 is fatally flawed because it is based upon the false assertion by NIEHS/HHS that the negative mutagenicity assay of sample "A07496" demonstrates that the TR494 test article, Lot 5893, was not mutagenic when the TR494 studies were conducted. In its 2008 denial of CPC's RFR, NIEHS/HHS asserted the blatant fiction that "BioReliance confirmed assignment of each test article aliquot number to the correct lot of anthraquinone". The fallacy in this critical assertion should be obvious to EPA based upon the submitted BTL Test Article Report; BioReliance did not assign test article aliquot numbers to numbered lots of

anthraquinone. BioReliance had no knowledge of the provenance of sample "A07496".

2. The TR494 test article was mutagenic when animal tests were conducted. The 9,10-AQ PPRTV and the study quality evaluation contained in EPA's response to RFC #18001 are not valid because they are based upon the fiction that the TR494 test article was not mutagenic.

3. EPA should withdraw the 9,10-AQ PPRTV, and remove 9,10-AQ from the RSL Tables because there is no scientifically valid justification for its inclusion in EPA's RSL Tables at this time.

I look forward to confirmation that I will be allowed (1) to attend presentation of this RFR to EPA's expert panel, (2) to make a presentation to EPA's expert panel, and (3) to invite the Chief of Staff for Congressman Barry Loudermilk, Rob Adkerson, to attend the presentations before EPA's expert panel.

Sincerely,



Jerry A. Cook  
Technical Director

RFR Attachment 1 – CPC's RFC #18001

RFR Attachment 2 – EPA's response to CPC's RFC #18001

RFR Attachment 3 – Deputy Director Samuel H. Wilson's conclusions

## RFR Attachment 1

RFC #18001 submitted by Chemical Products Corporation



CHEMICAL PRODUCTS CORPORATION  
CARTERSVILLE, GEORGIA 30120

POST OFFICE BOX 2470  
2144

TELEPHONE 770-382-  
FAX 770-386-6053

April 6, 2018

Via Certified Mail and Electronic Mail (quality@epa.gov)

USEPA Headquarters  
William Jefferson Clinton Federal Building  
1200 Pennsylvania Avenue, NW  
Mail Code: 2821T  
Washington, DC 20460

Subject: Request for Correction of "Anthraquinone, 9,10-" data  
- Screening levels for "Anthraquinone, 9,10-" in EPA's Regional  
Screening Level Tables displayed on EPA's website at  
<https://www.epa.gov/risk/regional-screening-levels-rsls-generic-tables-november-2017>

- provisional screening values presented in Appendix A of "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011

Dear Sir or Madam:

This Request for Correction is submitted by Chemical Products Corporation (CPC), a Georgia corporation located at 102 Old Mill Road SE, Cartersville, GA 30120. CPC hereby petitions EPA to correct information disseminated in "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 (PPRTV); and EPA's Regional Screening Level (RSL) Tables provided on EPA's website at <https://www.epa.gov/risk/regional-screening-levels-rsls-generic-tables-november-2017>.

The screening levels presented in EPA's RSL tables for the compound "Anthraquinone, 9,10-" are based upon the PPRTV which cites National Toxicology Program (NTP) Technical Report 494 (TR-494) as the principal study on which the provisional screening values presented in its Appendix A are based. TR-494 presents conclusions which are not

scientifically sound and do not comply with the U.S. Environmental Protection Agency's (EPA's) implementing guidelines (EPA Guidelines),<sup>1</sup> as a result, the "Anthraquinone, 9,10-" screening levels presented in EPA's Regional Screening Level (RSL) Tables do not reflect the "sound and objective scientific practices" required under the EPA Guidelines.

This Request for Correction is submitted under the Information Quality Act<sup>2</sup> and the EPA Guidelines, as well as the guidelines of the Office of Management and Budget (OMB)<sup>3</sup> and other applicable law.

CPC purchases 9,10-Anthraquinone as a 99% pure coarse powder and processes it into a fine-particle-size aqueous 50% solids suspension product which is sold primarily within the U.S. for use as a catalyst in the Kraft pulping process. The information in EPA's Regional Screening Level Tables disseminated to the public on EPA's website at <https://www.epa.gov/risk/regional-screening-levels-rsls-generic-tables-november-2017>. has harmed CPC by having an adverse effect on the sales of its product.

This Request for Correction will demonstrate that EPA should not consider the conclusions presented in National Toxicology Program Technical Report 494 (TR-494) to represent valid peer-reviewed toxicity values or sound science because peer reviewers were presented false information by NTP staff which prevented the Peer Review Panel from rendering a sound scientific judgment.

---

1 EPA, Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity of Information Disseminated by the Environmental Protection Agency (Oct. 2002).

2 Section 515(a) of the Treasury and General Government Appropriations Act for Fiscal Year 2001, P.L. 106-554; 44 U.S.C. § 3516 (notes).

3 67 Fed. Reg. 8452 (Feb. 22, 2002).

There is no scientifically sound basis for considering non-mutagenic 9,10-Anthraquinone (AQ) likely to be carcinogenic to humans. There is no scientifically sound basis for concluding that non-mutagenic 9,10-Anthraquinone (AQ) caused cancers in the NTP TR494 animal studies. NTP unknowingly conducted animal testing with AQ contaminated by the potent mutagen 9-nitroanthracene. When the mutagenic contamination was discovered years after completion of animal testing, NTP staff presented false information to a subsequent peer review panel in order to achieve acceptance of the conclusions presented in TR-494: that AQ caused carcinogenicity in female F344/N rats and both male and female B6C3F1 mice and some evidence of carcinogenicity in male F344/N rats.

The PPRTV cited in EPA's RSL Summary Table as the basis for the screening levels presented in the table is "*Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)*"; Superfund Health Risk Technical Support Center; EPA/690/R-11/007F Final 2-17-2011. In this document, Table 2 on pages 5 through 7 identifies the principal study upon which the subchronic, chronic, and carcinogenic toxicity determinations are based as "NTP(2005b)"; the reference on Page 50 shows "NTP(2005b)" to be "NTP technical report on the toxicology and carcinogenesis studies of anthraquinone (CAS no. 84-65-1) in F344/N rats and B6C3F1 mice (feed studies). NTP TR 494; NIH Publication No. 05-3953. U.S. Department of Health and Human Services, Public Health Service, Research Triangle Park, NC. Available online at <http://ntp.niehs.nih.gov/files/TR494web1.pdf>. Accessed on 4/8/2010." Thus, the information disseminated by EPA regarding 9,10-Anthraquinone in both the PPRTV and the RSL Summary Tables derives solely from National Toxicology Program Technical Report 494. This Request for Correction provides documentation that Technical Report

494 does not represent sound science or the "sound and objective scientific practices" required under the EPA Guidelines.

#### Historical Background of NTP Technical Report 494

The AQ employed in the TR-494 animal testing was obtained by NTP in the early 1990s; animal testing was completed in 1997; mutagenic contamination in the AQ test article was discovered in 2000 and two separate aliquots of the TR-494 test article were tested and found to be mutagenic soon thereafter. In December 2004 NTP presented false information to peer reviewers to achieve acceptance of the conclusions that NTP's animal studies provided clear evidence that AQ caused carcinogenicity in female F344/N rats and both male and female B6C3F1 mice. A negative mutagenicity assay falsely ascribed to the TR-494 test article was employed at the third peer review of TR-494 to convince peer reviewers that contamination was not biologically significant.

9,10-Anthraquinone (AQ) is not mutagenic. NTP unknowingly obtained AQ contaminated with the potent mutagen 9-nitroanthracene in the early 1990s for its animal testing; this AQ was produced in Europe because there is no U.S. domestic production of AQ. In the 1980s European toxicologists had determined that mutagenicity found only in commercial AQ produced by the nitric acid oxidation of anthracene process resulted from contamination by the potent mutagen 9-nitroanthracene. The obsolete nitric acid oxidation of Anthracene process was discontinued by the mid 1990s (soon after NTP obtained the AQ employed for animal testing). The nitric acid oxidation of anthracene process for production of AQ is not practiced anywhere in the world. All of the commercially-available AQ around the world today is free of 9-nitroanthracene contamination and is not mutagenic.

At the time it was conducting animal testing, NTP also provided aliquots of its AQ test article to other laboratories for additional toxicological testing.<sup>4</sup>

In 1999, when contamination of NTP's AQ test article with the potent mutagen 9-nitroanthracene had not yet been discovered, a peer review panel accepted NTP's proposed conclusion that AQ was responsible for clear evidence of carcinogenicity in female F344/N rats and both male and female B6C3F1 mice and some evidence of carcinogenicity in male F344/N rats. This 1999 peer-reviewed TR-494 was withdrawn in 2003.

Chemical analysis of NTP's AQ test article discovered the presence of the potent mutagen 9-nitroanthracene in 2000. The TR-494 AQ test article, labeled "Anthraquinone, Lot #5893", has been stored under air at room temperature at Battelle Columbus Labs since completion of animal testing in 1997. The concentration of 9-nitroanthracene in the test article may have decreased as a result of decomposition by the time it was detected in 2000.

NTP had not previously performed mutagenicity testing on its TR-494 AQ test article and it did not perform mutagenicity testing on its TR-494 test article after the 9-nitroanthracene contamination was detected.

CPC had an aliquot of NTP's test article tested by Bioreliance Testing

---

<sup>4</sup> Gibson, D.P., Brauninger, R., Shaffi, H.S., Kerckaert, G.A., LeBoeuf, R.A., Isfort, R.J., and Aardema, M.J. (1997). Induction of micronuclei in Syrian hamster embryo cells: Comparison to results in the SHE cell transformation assay for national toxicology program test chemicals. *Mutat. Res.* **392**, 61-70.

Laboratory in 2000 using the NTP test protocol and the aliquot was found to be mutagenic; this mutagenicity assay was reported to NTP.

Butterworth et al. also obtained an aliquot of NTP's AQ test article which was tested and was also found to be mutagenic.<sup>5</sup>

On September 8, 2003, Dr. Samuel H. Wilson, Deputy Director of NIEHS, withdrew the draft NTP Technical Report 494 which had been peer reviewed and accepted in 1999 because he determined that the presence of mutagenic contamination in non-mutagenic AQ had confounded interpretation of the NTP animal studies. Dr. Wilson informed CPC of the withdrawal of the 1999 peer-reviewed TR-494 in a letter which is included as Attachment 1.

Deputy Director Wilson's letter to CPC announcing the withdrawal of the 1999 TR-494 states in part:

*"Conclusions:* Following the process outlined above and after careful review of the information that I have described, I have reached the following conclusions:

1. The sample of anthraquinone used in the NTP 2-year study was contaminated with 9- nitroanthracene at a level of about 0.1%.
2. The presence of this contaminant raises doubt as to the effect(s) of anthraquinone itself, or its metabolites, and confounds interpretation of the NTP studies referenced in draft

---

<sup>5</sup> Butterworth, B.E., Mathre, O.B., and Ballinger, K. (2001). The preparation of anthraquinone used in the National Toxicology Program cancer bioassay was contaminated with the mutagen 9-nitroanthracene. *Mutagenesis* **16**, 169-177.

TR-494. In addition, in view of imprecise statements in the text presented on the website, this abstract needs to have greater specificity than it presently has.

3. The abstract of draft TR-494 will immediately be removed from the NTP website."

The same conclusions which appeared in the 1999 draft TR-494 appear in the final 2005 TR-494.

The NTP peer review panel responsible for approving the conclusions in TR-494 met on December 9, 2004 and were presented "new information": a negative mutagenicity assay for "Sample A07496" which NTP staff alleged to be a mutagenicity assay of the TR-494 AQ test article, all of which is stored at Battelle Columbus Laboratories and identified as "Anthraquinone, Lot #5893". This negative mutagenicity assay for "Sample A07496" is included in the 2005 TR-494.

A 2009 paper, [A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards](#), by eminent European toxicologist Alan R. Boobis<sup>6</sup> and co-authors contains the highly significant conclusion regarding the scientific validity of TR-494, "The data for anthraquinone are considered suspect

---

<sup>6</sup> Professor Alan R. Boobis received the Order of the British Empire in 2003 for his contributions on the risk assessment of pesticides. He is an Honorary Member of EUROTOX, a Fellow of the British Toxicology Society, and a Fellow of the Institute of Biology.

because other carcinogenicity studies were negative, and the NTP carcinogenicity study used a batch of anthraquinone contaminated with the potent mutagen 9-nitroanthracene at a level of 1,200 ppm (Butterworth, Mathre, and Ballinger 2001). (A purified sample was negative in the Ames test.) Certainly, it can be said that the material used by the NTP was mutagenic...."<sup>7</sup> As stated earlier, European toxicologists identified and traced the source of mutagenicity in AQ produced by the nitric acid oxidation of anthracene to 9-nitroanthracene contamination (NTP's Kristine Witt confirmed in the email included in Attachment 2 that nitric acid oxidation of anthracene was the production method for the NTP TR-494 test article).

The following false information was presented to the December 9, 2004 NTP Board of Scientific Counselors Peer Review Panel which approved the conclusions in TR-494:

**1.** The negative mutagenicity assay of "Sample A07496" was presented as definitive proof that 9-nitroanthracene contamination in NTP's TR-494 AQ test article was not biologically significant. Documents obtained through Freedom of Information Act requests reveal that "Sample A07496" is not an aliquot of NTP's AQ test article.

---

<sup>7</sup> Boobis, A.R. et al.; A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards; *Toxicologic Pathology* 2009; 37; 714.



The mutagenicity assay of "Sample A07496" was conducted by BioReliance Testing Laboratories in June 2004. Freedom of Information Act requests for information on shipments of AQ from Battelle Columbus Laboratories, the repository for all TR-494 AQ test article, to BioReliance Laboratories in the mid-2004 time period have not revealed any shipments of "Anthraquinone, Lot #5893" to BioReliance. Any aliquot of the TR-494 AQ test article shipped from Battelle would be labeled "Anthraquinone, Lot #5893".

When BioReliance Testing Laboratory reported the negative mutagenicity assay of "Sample A07496" to NTP, someone at NTP alleged, without providing any documentary evidence, that this was an aliquot of the TR-494 AQ test article "Anthraquinone, Lot #5893". Kristine Witt at NTP sought to verify the identity of "Sample A07496" by asking for confirmation from BioReliance Testing Laboratory that "Sample A07496" was an aliquot of "Anthraquinone, Lot #5893". Emails obtained through Freedom of Information Act requests are included as Attachment 2. Kristine Witt clearly states to Richard San at BioReliance that there is no documentation within NTP to demonstrate that "Sample A07496" is an aliquot of NTP's TR-494 AQ test article; she is forced to rely solely upon confirmation from BioReliance Testing Laboratory. Richard San at BioReliance emailed confirmation to Kristine Witt at NTP that "Sample A07496" was "Anthraquinone, Lot #5893" even though the BioReliance Test Article Receipt and Transfer Report demonstrates that no information existed within BioReliance Testing Laboratory to justify his confirmation.

The BioReliance Test Article Receipt and Transfer Report obtained through a Freedom of Information Act request shows that the sample in question was labeled only "Sample A07496" when it was received by BioReliance; BioReliance had no evidence that this sample was an aliquot of the TR-494 test article, "Anthraquinone, Lot #5893". The BioReliance Test Article Receipt and Transfer Report for "Sample A07496" is included as Attachment C.

Any aliquot of the TR-494 AQ test article would have been labeled "Anthraquinone, Lot #5893" when it was shipped from the Battelle Columbus Laboratories repository and when it was received by BioReliance Testing Laboratory. Someone at NTP arranged for the shipment of "Sample A07496" to BioReliance Testing Laboratories and authorized mutagenicity testing of a sample labeled "Sample A07496" by BioReliance with full knowledge that this AQ sample was not the TR-494 test article.

To sum, peer reviewers were under the false impression that the TR-494 AQ test article had been determined to be non-mutagenic when they approved the conclusions in TR-494, and TR-494 contains this false allegation. This false information would have been critical to their adjudication and renders their acceptance of the conclusions in TR-494 scientifically untenable.

**2.** During the December 9, 2005 peer review, a reviewer questioned whether mutagenic impurities might have decomposed during the roughly 8 year period between animal testing and the June 2004 negative mutagenicity assay; the possibility of decomposition of biologically significant mutagenic impurities in

the TR-494 test article over time confounds interpretation of a 2004 negative mutagenicity assay, even if the assay had been performed on an aliquot of the TR-494 test article. The Peer Review Panel was told by NTP's Cynthia Smith that the aliquot of the test article which underwent mutagenicity assay in June 2004 had been stored frozen under argon during the interval between animal testing and mutagenicity assay. Peer reviewers were provided false information; documents obtained under a Freedom of Information Act request showed that all TR-494 test article had been stored at room temperature under air for this 8 year period. In response to a Request for Correction, NTP opted to simply add an addendum paragraph after the last page of TR-494 rather than address the impact this false information had on peer reviewer's adjudication of the conclusions in TR-494.

In sum, peer reviewers were provided false information to prevent them from accurately evaluating the scientific validity of the conclusions presented in TR-494. The same conclusions that were approved in 1999 prior to discovery of mutagenic contamination in the TR-494 test article were approved on December 9, 2004 for inclusion in the final TR-494.

---

The EPA Guidelines require "influential" scientific information to meet a "higher degree of quality."<sup>8</sup> In particular, EPA has established very rigorous standards for "influential scientific risk assessment information."<sup>9</sup> These stringent quality standards are applicable here.

---

<sup>8</sup> EPA Guidelines at p. 19-20. Likewise, OMB has declared that: "The more important the information, the higher the quality standards to which it should be held." 67 Fed. Reg. At 8452.

<sup>9</sup> EPA Guidelines at pp. 20-23.

Other Required Information: The EPA Guidelines require Requests for Correction to include the name and contact information of the organization submitting the request, and to identify an individual to serve as a contact. For this Request, the name of the organization submitting the request is Chemical Products Corporation, a Georgia corporation, located at 102 Old Mill Road SE, Cartersville, GA 30120; and contact information is as follows:

Jerry A. Cook, Technical Director  
Chemical Products Corporation  
102 Old Mill Road SE  
P.O. Box 2470  
Cartersville, GA 30120


---

Conclusion: For the reasons set forth above, CPC respectfully requests that:

- (1)** this Request for Correction be granted;
- (2)** "Anthraquinone, 9,10-" be immediately removed from EPA's Regional Screening Level Tables provided on EPA's website at <https://www.epa.gov/risk/regional-screening-levels-rsls-generic-tables-november-2017> pending revision of "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 to provide toxicity values for 9,10-Anthraquinone which are based upon sound science;

**(3)** "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 be immediately withdrawn and revised to provide toxicity values for 9,10-Anthraquinone which are based upon sound science rather than upon NTP Technical Report 494.

Very truly yours,



Jerry A. Cook  
Technical Director

Attachments – 12 pages

- Attachment 1 – 3 pages – contains Deputy Director Samuel H. Wilson letter to CPC announcing withdrawal of the peer-reviewed 1999 TR-494
- Attachment 2 – 6 pages – contains 2 emails from NTP's Kristine Witt to Richard San at BioReliance Testing Laboratory and 2 emails from Richard San to Kristine Witt.
- Attachment 3 – 3 pages – contains the Test Article Receipt and Transfer Report from BioReliance Testing Laboratory showing receipt of a sample labeled only "Sample A07496".

cc: **Via Certified Mail and Electronic Mail**

Dr. Tina Bahadori, Director  
EPA National Center for Environmental Assessment  
(Bahadori.tina@epa.gov)

## Attachment 1

Deputy Director Samuel H. Wilson's letter to CPC  
announcing withdrawal of the  
peer-reviewed 1999 TR-494  
after discovery of mutagenic contamination  
in the AQ test article



September 8, 2003

**National Institutes of Health  
National Institute of  
Environmental Health Sciences  
P.O. Box 12233  
Research Triangle Park, N.C. 27709  
Website: [www.niehs.nih.gov](http://www.niehs.nih.gov)**

Mr. Jerry A. Cook  
Technical Director  
Chemical Products Corporation  
Cartersville, Georgia 30120

Re: Request for Reconsideration submitted March 27, 2003

Dear Mr. Cook:

On behalf of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), I am responding to your March 27, 2002, Request for Reconsideration submitted for the Chemical Products Corporation (CPC) under the NIH's "Guidelines for Ensuring the Quality of Information Disseminated to the Public" (NIH Guidelines). Your Reconsideration Request appealed the NIH's March 19, 2003, decision regarding the CPC's November 15, 2003, Request for Correction contained in the Abstract for Draft National Toxicology Program (NTP) Technical Report # TR-494. A summary of the background information on the study that culminated in draft TR-494, the process I used to consider the appeal, and my conclusions are provided as follows:

*Background:* The NTP conducted a 2-year carcinogenicity study in rodents on a batch of anthraquinone obtained commercially that was shown to be 99.9% pure; results of this study eventually led to a draft report termed TR-494. Once it was peer reviewed, the abstract of draft TR-494 was posted on the NTP website. On July 25, 2000, you sent a letter to Dr. Kenneth Olden, Director of the NTP, stating that the sample of anthraquinone tested contained a 0.1% contamination by 9-nitroanthracene, a mutagenic compound, and noting that the presence of this contaminant called the study interpretations into question. The NTP followed up on your letter, confirming that a contaminant in the anthraquinone sample at about the 0.1% level was indeed 9-nitroanthracene. The NTP then initiated the process, in September 2000, to assess the metabolism of the parent compound, anthraquinone, in rodents, and to assess the relative mutagenicity in an Ames test of anthraquinone, its two major urinary metabolites, the contaminant 9-nitroanthracene, and two isomers of 9-nitroanthracene. You subsequently filed an Information Quality Request for Correction on November 15, 2002, asking that the abstract be immediately removed from the NTP's website in view of errors or misleading statements in the material presented. On March 19, 2003, NIH sent you a response to your Request for Correction stating that additional information would be incorporated into the NTP web site to clarify the material in the abstract of draft TR-494 and informing you about ongoing follow-up studies of

anthraquinone. The NTP amended the abstract of draft TR-494 on April 1, 2003, on its website to include reference to the 9-nitroanthracene contaminant, and the NTP also made mention of ongoing studies to resolve whether or not this contaminant might have affected the 2-year study results. On March 27, 2003, you submitted a Request for Reconsideration to NIH.

*Process:* In the course of my review, I have reviewed the HHS and NIH Guidelines for Ensuring the Quality of Information Disseminated to the Public, read draft TR-494, and read Chemical Products Corporation's letters and the NTP's responses to those letters. I have consulted with NIH and HHS staff familiar with the Information Quality process. I also have reviewed data and ongoing tests with the staff of NIEHS' Environmental Toxicology Program who were responsible for the NTP studies and draft report. I have been assisted in these efforts by staff from the NIEHS Office of Policy, Planning and Evaluation.


*Conclusions:* Following the process outlined above and after careful review of the information that I have described, I have reached the following conclusions:

1. The sample of anthraquinone used in the NTP 2-year study was contaminated with 9-nitroanthracene at a level of about 0.1%.
2. The presence of this contaminant raises doubt as to the effect(s) of anthraquinone itself, or its metabolites, and confounds interpretation of the NTP studies referenced in draft TR-494. In addition, in view of imprecise statements in the text presented on the website, this abstract needs to have greater specificity than it presently has.
3. The abstract of draft TR-494 will immediately be removed from the NTP website.

Further studies are underway on the metabolism of anthraquinone in rodents and on the relative mutagenic potency of this compound, its major metabolites, the contaminant 9-nitroanthracene, and two isomers of 9-nitroanthracene. Additional information from this work will eventually be incorporated into a revised abstract and technical report which will be submitted for peer review and subsequent publication.

I appreciate your comments and hope that the actions that I have taken address your concerns.

Sincerely,



Samuel H. Wilson, M.D.  
Deputy Director

cc: Mary Wolfe, Ph.D.  
Director, NTP Liaison and Scientific Review Office



## Attachment 2

emails exchanged between NTP's Kristine Witt and Richard San at BioReliance Testing Laboratory about 3 months prior to the final peer review of TR-494

contains 2 emails from NTP's Kristine Witt to Richard San and 2 emails from Richard San to Kristine Witt

In Kristine Witt's first email she describes the TR-494 test article as  
" Anthraquinone, Lot #5893.  
This is from Zeneca Fine Chemicals.  
The Nitric Acid Oxidation manufacturing process"

In Kristine Witt's second email she states,  
"...without confirmation of the test article identities I'm uncertain as to what the results are telling us."

> **From:** Witt, Kristine (NIH/NIEHS[<mailto:witt@niehs.nih.gov>])  
> **Sent:** Friday, September 10, 2004 9:43 AM  
> **To:** San, Richard <[RSan@bioreliance.com](mailto:RSan@bioreliance.com)>  
> **Subject:** FW: question about aliquot number assignment

>  
>  
> Hello, Richard.

>  
> Thank you for sending the preliminary results for the 4  
> Salmonella tests that were recently conducted at  
> BioReliance. The results were surprising to me, and  
> therefore, I need to make sure that your aliquot  
> assignment matches ours. Can you please confirm that the  
> aliquot numbers match the chemical samples described  
> below? If there is a discrepancy, please send me your list,  
> matching aliquot with test sample.

>  
> Regarding the issue of money for the no-cost extension,  
> our contract officer is aware of the problem and he is  
> considering an approach to resolving the problem.

>  
> Thanks for your help in understanding these test results.

>  
> Best regards,  
> Kristine.

>  
> > 4 aliquot numbers were assigned to 4 different samples of  
> > anthraquinone. They were:

> >  
> > A07496 1. Anthraquinone, Lot #5893. This is from  
> > Zeneca FineChemicals. The Nitric Acid Oxidation  
> > manufacturing process (78.82 kg).

> >

> > A40147 2. 9,10-Anthraquinone, Lot #2Y011. This is  
> > from Kawasaki Kasei Chemical LTD. The Diels-Alder  
> > manufacturing process (13.40 kg).

> >

> > A65343 3. 9,10-Anthraquinone, Lot # 64005. This is  
> > from Environmental Biocontrol Intl. The Diels-Alder  
> > manufacturing process.  
> > (23.20 g).

> >

> > A54984 4. 9,10-Anthraquinone, Lot # GSTU 2517770.  
> > This is from Environmental Biocontrol Intl. The Friedel-  
> > Crafts manufacturing process. (26.70 g).

> >

> > Kristine L. Witt  
> > Toxicology Operations Branch  
> > Environmental Toxicology Program  
> > National Institute of Environmental Health Sciences  
> > PO Box 12233, MD EC-32  
> > Research Triangle Park, NC 27709  
> > phone: 919-541-2761  
> > fax: 919-316-4511  
> > e-mail: [witt@niehs.nih.gov](mailto:witt@niehs.nih.gov)

> >

> >

>

>

> **From:** San, Richard <[RSan@bioreliance.com](mailto:RSan@bioreliance.com)>  
> **Sent:** Friday, September 10, 2004 4:44 PM  
> **To:** Witt, Kristine (NIH/NIEHS) <[witt@niehs.nih.gov](mailto:witt@niehs.nih.gov)>  
> **Subject: RE:** question about aliquot number assignment

>

> Hello, Kristine,>

> Thanks for your e-mail. I have asked [*non-key employee*];  
> who has custody of the test article related documents, to  
> confirm the aliquot assignments. As soon as I hear from  
> him, I will let you know.

>

> Best regards,

>

> Richard

>

**From:** Witt, Kristine (NIH/NIEHS) [<mailto:witt@niehs.nih.gov>]

**Sent:** Wednesday, September 15, 2004 3: 18 PM

**To:** San, Richard <[RSan@bioreliance.com](mailto:RSan@bioreliance.com)>

**Subject: RE:** question about aliquot number assignment

Hi, Richard.

Have you received word from [*non-key employee*] about the test article aliquot number assignments? We are having a meeting here Friday morning to review all the new data we've acquired on anthraquinone and try to understand what it means in terms of biological activity for some important commercial compounds. These data are key to that discussion, but without confirmation of the test article identities I'm uncertain as to what the results are telling us. Can you please let [*non-key employee*] know that the need for the information you requested is urgent?

Thanks,  
Kristine.

**Subject: RE: question about aliquot number assignment**

**Date:** Thursday, September 16, 2004 2:26 PM

**From:** San, Richard <[RSan@bioreliance.com](mailto:RSan@bioreliance.com)>

**To:** "Witt, Kristine (NIH/NIEHS)" <[witt@niehs.nih.gov](mailto:witt@niehs.nih.gov)>

**Conversation:** question about aliquot number assignment

Hello, Kritine,

[*non-key employee*] has confirmed that the test article aliquot number assignments are accurate as presented. Also, from a review of the study files, it is noted that we have a Material Safety Data Sheet only for A40147 from Kawasaki Kasei Chemical LTD.

Regards,

Richard

## Attachment 3

the Test Article Receipt and Transfer Report  
from BioReliance Testing Laboratory  
recording receipt of a sample  
labeled only  
"Sample A07496"

BioReliance reported a negative mutagenicity assay  
of this sample  
to NTP

Compiled date 15-DEC-2006 01:30 PM

Lot.Sample: AA93WK.0001

Lot.Sample: AA93WK.0001  
 Test Article Name: A07496  
 Label ID: A07496 store at RT No Exp Date given Sieved 8 mesh  
 Lot/Batch No: NP  
 Expiration: N/A  
 Purity: NP  
 Storage Condition: Room Temperature  
 Stock Locator: 15-30\*RM5275B\*CAB1/3C\*BTL  
 Supplement Storage: protect from light/desiccate  
 Description: light yellow powder (per MSDS: light tan liquid)  
 Gross Weight: 32.32 g  
 Net Weight: NP  
 Unit of Measure: G  
 Handling: Non-regulated  
 Condition on Rcpt: GOOD  
 Receipt Date: 02-JUN-2004  
 Login By: [Non-Key Contract Emp]  
 Login Date: 04-JUN-2004  
 Comments: received TA ambient with papers. Logged in TA late on 6/4/04 (received on 6/2/04) due to the fact that the Sponsor Site in the Oracle Module was inactive. Changed location number because of change of RM#

From Subinv	From Locator	# Units	UOM	Trx Date	System Date	To Subinv	To Locator	User
		32.32	G	04-JUN-2004	04-JUN-2004	BTL-CHMREP	3*RT*MCDDRM261*3C	
BTL-CHMREP	3*RT*MCDDRM261*3C	600.00	MG	16-JUN-2004	16-JUN-2004	BTL-GAMES		
BTL-CHMREP	3*RT*MCDDRM261*3C	100.00	MG	16-JUN-2004	16-JUN-2004	BTL-GAMES		

[Non-7 Key Contract Employee]



Compiled date 15-DEC-2006 01:30 PM

Lot.Sample: AA93WK.0001

From Subinv	From Locator	# Units	UOM	Trx Date	System Date	To Subinv	To Locator	User
BTL-CHMREP	3*RT*MCDDRM261*3C	480.00	MG	16-JUN-2004	16-JUN-2004	BTL-GAMES		[Non- Key Contract Employee]
BTL-CHMREP	3*RT*MCDDRM261*3C	200.00	MG	15-JUL-2004	15-JUL-2004	BTL-GAMES		
BTL-CHMREP	3*RT*MCDDRM261*3C	30.94	G	20-OCT-2005	20-OCT-2005	BTL-CHMREP	15-30*RMS275B*CAB1/3C	

CHEMICAL PRODUCTS CORPORATION  
CARTERSVILLE, GEORGIA 30120

POST OFFICE BOX 2470

TELEPHONE 770-382-2144  
FAX 770-386-6053

April 20, 2018

Via Certified Mail and Electronic Mail (quality@epa.gov)

USEPA Headquarters  
William Jefferson Clinton Federal Building  
1200 Pennsylvania Avenue, NW  
Mail Code: 2821T  
Washington, DC 20460

Subject: Information Quality Guidelines (IQG) identifier:  
**RFC #17003**

---

Additional Information demonstrating that National Toxicology Program Technical Report 494 should not be the basis for provisional screening values presented in Appendix A of "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 or the screening levels for "Anthraquinone, 9,10-" in EPA's Regional Screening Level Tables

Dear Sir or Madam:

This letter contains additional information to supplement the Request for Correction submitted by Chemical Products Corporation (CPC) on April 6, 2018, assigned Information Quality Guidelines Identifier **RFC #17003**.

The contents of this letter provide yet another sufficient reason to conclude that the National Toxicology Program (NTP) peer review panel which accepted the conclusions presented in NTP Technical Report 494 (TR-494) were not presented accurate information, thus, the peer review panel was unable to render a sound scientific judgment regarding the conclusions presented in TR-494. The peer review of TR-494 does not meet the "sound and objective scientific practices"

April 20, 2018

requirement contained in the EPA Guidelines and should not be accepted by EPA as a valid peer review. EPA should not base the provisional screening values presented in Appendix A of "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 (PPRTV), or the screening levels presented in EPA's RSL tables for the compound "Anthraquinone, 9,10-" on TR-494.

The primary metabolite of 9,10-Anthraquinone (AQ) is incorrectly stated to be 2-Hydroxyanthraquinone in TR-494. Sato et al. (1959) corrected Sato et al. (1956) which is cited in TR-494, but Sato et al. (1959) is not cited in TR-494. Sato et al. (1959) (Attachment 1) reported that only a very small quantity of 2-Hydroxyanthraquinone was found in fresh rat urine.

TR-494 states on page 91, "2-Hydroxyanthraquinone is the major anthraquinone metabolite present in urine regardless of the method of anthraquinone synthesis. Lesser amounts of 1-hydroxyanthraquinone were also present. That 2-hydroxyanthraquinone is a major metabolite of anthraquinone is in agreement with results reported by Sato et al. (1956)...". However, in 1959 Sato et al. Reported, "In a previous study anthraquinone was fed to rats and 2-hydroxyanthraquinone was recovered from the urines (1). However, its quantity was found to be very small when freshly voided urine was examined by paper chromatography. This fact suggested that the urine contained a substance which liberated 2-hydroxyanthraquinone on standing. Using S<sup>35</sup>-sulfate a sulfate conjugate of 2-hydroxyanthraquinone was found."

April 20, 2018

Sato et al. (1956) was corrected by the authors in Sato et al. (1959) which reports that the primary metabolite of 9,10-anthraquinone found in rat urine is not 2-Hydroxyanthraquinone, but rather the sulfate conjugate of 2-Hydroxyanthraquinone which decomposes on standing to sulfate and 2-Hydroxyanthraquinone. In this context, the term "conjugate" in organic chemistry refers to a compound formed by the joining of two or more chemical compounds. Sato et al. (1959) describes how 2-Hydroxyanthraquinone was reacted with chlorosulfonic acid and chloroform to form the sulfate conjugate of 2-Hydroxyanthraquinone for use as the lab standard to verify the identity of the compound in fresh rat urine. NTP did not inform peer reviewers of Sato et al. (1959) and it is not cited in TR-494. Instead, NTP presented its positive mutagenicity assay of 2-Hydroxyanthraquinone as documenting mutagenicity in the primary AQ metabolite.

There is a typographical error in "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 (PPRTV) at page 16 where "2-hydroxyanthracene" is written instead of "2-hydroxyanthraquinone", the purported primary metabolite of AQ in TR-494. The PPRTV states, beginning at the bottom of page 16, "NTP (2005b), however, found that the mutagenicity of 2-hydroxyanthracene, a major metabolite of 9,10-anthraquinone, was 7 times as mutagenic as 2-NA and would be a much more likely candidate for the causative agent, if mutagenicity was involved in the mode of action." Contamination of the TR-494 test article by 9-nitroanthracene (9-NA) is at issue, not contamination by 2-nitroanthracene (2-NA).

There is no scientifically sound basis for considering non-mutagenic 9,10-Anthraquinone (AQ) likely to be carcinogenic to humans. There is

April 20, 2018

no scientifically sound basis for concluding that non-mutagenic 9,10-Anthraquinone (AQ) caused cancers in the NTP TR494 animal studies. NTP unknowingly conducted animal testing with AQ contaminated by the potent mutagen 9-nitroanthracene.

The 2009 paper, A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards, by eminent European toxicologist Alan R. Boobis and co-authors is included as Attachment 2. Please refer to page 719, in the first column below Table 2, where the authors state, "The data for anthraquinone are considered suspect because other carcinogenicity studies were negative, and the NTP carcinogenicity study used a batch of anthraquinone contaminated with the potent mutagen 9-nitroanthracene at a level of 1,200 ppm (Butterworth, Mathre, and Ballinger 2001)...."

To sum, in addition to the deficiencies detailed in CPC's April 6, 2018 Request for Correction submission, false information regarding the identity of the primary metabolite of AQ was provided to peer reviewers and incorporated into TR-494. The mutagenicity of the compound NTP incorrectly presented as being the primary metabolite of AQ would have had a significant impact on the peer reviewers' adjudication and renders their acceptance of the conclusions in TR-494 scientifically untenable.

---

The EPA Guidelines require "influential" scientific information to meet a "higher degree of quality." In particular, EPA has established very rigorous standards for "influential scientific risk assessment information." These stringent quality standards are applicable here.

April 20, 2018

---

Conclusion: For the reasons set forth above, CPC respectfully renews its requests that:

- (1)** Request for Correction, IQG identifier RFC #17003, be granted;
- (2)** "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 be immediately withdrawn and revised to provide toxicity values for 9,10-Anthraquinone which are based upon sound science rather than upon NTP Technical Report 494.
- (3)** "Anthraquinone, 9,10-" be immediately removed from EPA's Regional Screening Level Tables provided on EPA's website at <https://www.epa.gov/risk/regional-screening-levels-rsls-generic-tables-november-2017> until such time as "Provisional Peer-Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)", EPA/690/R-11/007F, Final 2-17-2011 is revised to provide scientifically sound toxicity values for 9,10-Anthraquinone which could justify its inclusion.

Very truly yours,



Jerry A. Cook  
Technical Director

Attachments – 23 pages

Attachment 1 – 3 pages – Sato et al. (1959)

Attachment 2 – 20 pages – Boobis et al. (2009)

cc: **Via Certified Mail and Electronic Mail**

Dr. Tina Bahadori, Director

EPA National Center for Environmental Assessment

(Bahadori.tina@epa.gov)

## METABOLISM OF ANTHRAQUINONE

## II. SULFATE CONJUGATE OF 2-HYDROXYANTHRAQUINONE

By TOKURO SATO, TAEKO SUZUKI

*(From the Institute of Public Health, Tokyo)*

AND HARUHISA YOSHIKAWA

*(From the Department of Nutrition and Physiological Chemistry,  
Faculty of Medicine, University of Tokyo, Tokyo)*

(Received for publication, March 11, 1959)

In a previous study anthraquinone was fed to rats and 2-hydroxyanthraquinone was recovered from the urines (1). However, its quantity was found to be very small when freshly voided urine was examined by paper chromatography. This fact suggested that the urine contained a substance which liberated 2-hydroxyanthraquinone on standing. Using  $S^{35}$ -sulfate a sulfate conjugate of 2-hydroxyanthraquinone was found.

## EXPERIMENTAL AND RESULTS

Rats were fed with anthraquinone in the same way as reported previously (1). About 100  $\mu$ c. of radioactive sulfate was injected subcutaneously into the rat and the urine excreted within the next 24 hour period was collected.

*Radioautography of the Chromatograms*—Ascending chromatography was carried out on Whatman No. 1 paper and the paper was subjected to radioautography. There appeared a spot with  $R_f$  value of 0.51 and 0.39 when run in butanol, acetic acid, water mixture (4:1:1), and in 3 *N*  $Na_2CO_3$ , 3 *N*  $NH_4OH$ , and butanol (3:3:9), respectively.

*Colour Reaction of the Substance on the Chromatogram*—The colour of this spot on the paper was pale yellow and gave no fluorescence under ultraviolet light. The colour did not change by spraying 10 per cent  $Na_2CO_3$  solution followed by diazotized sulfanilic acid. But after the paper was placed in an atmosphere of hydrogen chloride fume for 20 minutes at room temperature, the spot was coloured yellow and turned to red by spraying with alkali. This colour reaction of the hydrolyzed material was the same as that of 2-hydroxyanthraquinone.

The quantity of 2-hydroxyanthraquinone which was contained in this spot was not enough to account for all the concentration of 2-hydroxyanthraquinone found in the urine.

*Examination of the Acid Hydrolyzed Product of the Spot*—The radioactive spot

was cut out from the paper and eluted with water. Then the eluate was acidified with hydrogen chloride solution to a concentration of 1 *N* and heated at 100° for 1 hour. The solution was condensed by evaporation to a small volume and submitted to paper chromatography using different solvents as described in the previous report (1). The  $R_f$  values of the obtained spot were in good agreement with those of 2-hydroxyanthraquinone. The spot was cut out and eluted with alcohol. The absorption curve from 210  $m\mu$  to 600  $m\mu$  coincided with the authentic sample of 2-hydroxyanthraquinone (1). Inorganic  $S^{35}$ -sulfate was also detected, but no other product was found by fluorescence or colour reaction such as spraying with alkali or diazo reagents.

*Stability of the Compound*—This compound was labile in water and yielded 2-hydroxyanthraquinone on standing.

An attempt was made to recover the sulfate conjugate in a considerable quantity from rat urine by counter current technique using water and butanol as solvents; but the compound was almost completely decomposed during the manipulation.

*Synthesis of the Sulfate Conjugate of 2-Hydroxyanthraquinone*—10 mg. of 2-hydroxyanthraquinone was dissolved in 0.75 ml. of pyridine at 0°. To this was added slowly a mixture of 0.05 ml. of chlorosulfonic acid and 0.125 ml. of chloroform. The mixture was stirred for one hour and centrifuged. The supernatant was neutralized with potassium hydroxide solution and subjected to paper chromatography which showed a spot in the same location and with the same reactions and components as were found in the urine of rats fed with anthraquinone. Further purification was abandoned because it was decomposed easily by further manipulation.

Attempts were made, but without success, to conjugate  $S^{35}$ -sulfate with 2-hydroxyanthraquinone in rat liver slices or in the supernatant of rat liver homogenates by the method described before (2).

#### DISCUSSION

Rats were fed with anthraquinone and a metabolite which decomposed to sulfate and 2-hydroxyanthraquinone was found in the urine. By paper chromatography and colour reactions this substance was found to be the same with a compound recovered from a procedure to conjugate sulfate with 2-hydroxyanthraquinone. From this evidence the metabolite was concluded to be the sulfate conjugate of 2-hydroxyanthraquinone.

#### SUMMARY

Urine from rats fed anthraquinone and  $S^{35}$ -sulfate was examined by paper chromatography and colour reactions. A metabolite which decomposed to sulfate and 2-hydroxyanthraquinone was found, and it was concluded to be a sulfate conjugate of 2-hydroxyanthraquinone.



## REFERENCES

- (1) Sato, T., Fukuyama, T., Yamada, M., and Suzuki, T., *J. Biochem.*, **43**, 21 (1956)
- (2) Sato, T., Suzuki, T., Fukuyama, T., and Yoshikawa, H., *J. Biochem.*, **43**, 421 (1956)

## A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards

Alan R. Boobis, Samuel M. Cohen, Nancy G. Doerrler, Sheila M. Galloway, Patrick J. Haley, Gordon C. Hard, Frederick G. Hess, James S. Macdonald, Stéphane Thibault, Douglas C. Wolf and Jayne Wright  
*Toxicol Pathol* 2009; 37; 714 originally published online Aug 21, 2009;  
DOI: 10.1177/0192623309343779

The online version of this article can be found at:  
<http://tpx.sagepub.com/cgi/content/abstract/37/6/714>

---

Published by:



<http://www.sagepublications.com>

On behalf of:



Society of Toxicologic Pathology

**Additional services and information for *Toxicologic Pathology* can be found at:**

**Email Alerts:** <http://tpx.sagepub.com/cgi/alerts>

**Subscriptions:** <http://tpx.sagepub.com/subscriptions>

**Reprints:** <http://www.sagepub.com/journalsReprints.nav>

**Permissions:** <http://www.sagepub.com/journalsPermissions.nav>

## A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards

ALAN R. BOOBIS,<sup>1</sup> SAMUEL M. COHEN,<sup>2</sup> NANCY G. DOERRER,<sup>3</sup> SHEILA M. GALLOWAY,<sup>4</sup> PATRICK J. HALEY,<sup>5</sup>  
GORDON C. HARD,<sup>6</sup> FREDERICK G. HESS,<sup>7</sup> JAMES S. MACDONALD,<sup>8</sup> STÉPHANE THIBAUT,<sup>9</sup> DOUGLAS C. WOLF,<sup>10</sup> AND JAYNE WRIGHT<sup>11</sup>

<sup>1</sup>*Imperial College London, London, United Kingdom*

<sup>2</sup>*University of Nebraska Medical Center, Omaha, NE, 68131 USA*

<sup>3</sup>*ILSI Health and Environmental Sciences Institute, Washington, D.C., 20005 USA*

<sup>4</sup>*Merck Research Laboratories, West Point, PA, 619446 USA*

<sup>5</sup>*Incyte Corporation, Wilmington, DE, 619807 USA*

<sup>6</sup>*Private Consultant, Tairua, New Zealand*

<sup>7</sup>*BASF Corporation, Research Triangle Park, NC, 27709 USA*

<sup>8</sup>*Schering-Plough Research Institute, Kenilworth, NJ, 07033 USA*

<sup>9</sup>*Wyeth Research, Chazy, NY, 12921 USA*

<sup>10</sup>*U.S. Environmental Protection Agency, Research Triangle Park, NC, 27713 USA*

<sup>11</sup>*Syngenta, Jealotts Hill, United Kingdom*

### ABSTRACT

The two-year cancer bioassay in rodents remains the primary testing strategy for in-life screening of compounds that might pose a potential cancer hazard. Yet experimental evidence shows that cancer is often secondary to a biological precursor effect, the mode of action is sometimes not relevant to humans, and key events leading to cancer in rodents from nongenotoxic agents usually occur well before tumorigenesis and at the same or lower doses than those producing tumors. The International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) hypothesized that the signals of importance for human cancer hazard identification can be detected in shorter-term studies. Using the National Toxicology Program (NTP) database, a retrospective analysis was conducted on sixteen chemicals with liver, lung, or kidney tumors in two-year rodent cancer bioassays, and for which short-term data were also available. For nongenotoxic compounds, results showed that cellular changes indicative of a tumorigenic endpoint can be identified for many, but not all, of the chemicals producing tumors in two-year studies after thirteen weeks utilizing conventional endpoints. Additional endpoints are needed to identify some signals not detected with routine evaluation. This effort defined critical questions that should be explored to improve the predictivity of human carcinogenic risk.

**Keywords:** carcinogenesis; carcinogenicity testing; DNA reactivity; liver carcinogenesis; kidney carcinogenesis; lung carcinogenesis; immunosuppression; nongenotoxic carcinogens; mode of action.

---

Address correspondence to: Nancy G. Doerr, MS, ILSI Health and Environmental Sciences Institute, 1156 Fifteenth Street, NW, Second Floor, Washington, D.C. 20005, USA; e-mail: [ndoerr@hesiglobal.org](mailto:ndoerr@hesiglobal.org).

This article does not necessarily reflect the opinions or policy of the U.S. Environmental Protection Agency; nor does mention of trade names constitute endorsement. James S. MacDonald's current affiliation is Chrysalis Pharma Consulting, LLC.

Conflict of Interests: The authors have not declared any conflict of interests.

Abbreviations: AAF, 2-acetylaminofluorene; ALT, alanine transaminase; B[a]P, benzo[a]pyrene; CAR, constitutive androstane receptor; CHIS, Cancer Hazard Identification Strategies (HESI Project Committee); DNA, deoxyribonucleic acid; EPA, U.S. Environmental Protection Agency; HESI, Health and Environmental Sciences Institute; ICH, International Conference on Harmonisation; ILSI, International Life Sciences Institute; IPCS, International Programme on Chemical Safety; MN-NCE, micronucleated normochromatic erythrocytes; MN-PCE, micronucleated polychromatic erythrocytes; MOA, mode of action; NCI, National Cancer Institute; NOS, not otherwise specified; NTP, National Toxicology Program; OECD, Organisation for Economic Cooperation and Development; SCE, sister chromatid exchange; SDH, sorbitol dehydrogenase.

### I. INTRODUCTION

As part of the hazard identification of regulated chemicals and of those substances nominated to programs such as the National Toxicology Program (NTP), a lifetime bioassay of carcinogenic potential is routinely undertaken in rats and mice. This applies to most drugs, depending on likely duration of treatment, pesticides, veterinary medicines, and food additives. Many industrial chemicals and natural compounds are also subject to such testing. The rodent bioassay used for this purpose was originally developed in the 1940s and 1950s (Berenblum 1969; E. Weisburger 1981, 1983), and the underlying principles of the assay have remained largely unchanged since that time. The bioassay was based on the observation that exposure of experimental animals, as well as humans, to a number of chemicals led to development of cancer. However, at the time, there was little mechanistic understanding of chemical carcinogenesis. Analysis of the results of initial studies led to

the conclusion that the “majority of all cancer” is caused by chemical or environmental factors (Epstein 1979; Roe 1989). However, it should be noted that, at that time, “environmental” (which simply meant that the etiological factor was extrinsic) was often assumed to mean “chemical.” This led to a major focus on identifying chemical carcinogens on the assumption that this would enable the burden of cancer to be substantially reduced.

Inherent in the use of animals for the carcinogenicity bioassay is the assumption that humans and animals behave in a similar way (interspecies extrapolation). In addition, two experimental concepts form the scientific basis on which the bioassay is based.

The first is the empirical relationship developed by Druckrey (1967).

$$d \times t^n = \text{constant},$$

where  $d$  is dose;  $t$  is time to tumor appearance; and  $n$  is a power term, usually 2, 3, or even higher.

The experimental work, mostly with nitrosamines in liver, which led to this relationship, indicated that tumor incidence was directly proportional to dose (dose extrapolation). Thus, incidence could be increased by increasing the dose, or the time to tumor could be decreased, although there was a minimum interval before tumors developed. This approach, however, only worked for genotoxic (DNA reactive) carcinogens. It implied a multistage process for carcinogenesis. A version of this multistage theory derived from epidemiologic data had been previously postulated by Armitage and Doll (1954). However, numerous human tumors, such as Hodgkin lymphoma, breast cancer, osteogenic sarcomas, and childhood tumors, did not show this age relationship.

The second concept is that carcinogenesis comprises multistep stages, which was first demonstrated by the model of tumor initiation and promotion. This was developed to explain the observed data for chemical carcinogenesis in mouse skin by Berenblum and Shubik (1947, 1949). These studies showed that skin carcinogenesis first required a short exposure to certain chemicals, resulting in an irreversible change that was termed “initiation.” This had to be followed by prolonged exposure to other chemicals that acted to promote the initiated cells, the effects of which were reversible up to a certain time. This was termed “promotion.” In this model, chemicals that act as promoters do not act as initiators. Promotion has to be preceded by initiation; promotion does not need to commence immediately after initiation. It is now recognized that this distinction is not as clear-cut as once believed (see Goodman and Watson 2002).

The model was later shown to apply to a number of other cancer types in rats and mice. It also subsequently acquired a mechanistic interpretation, although the molecular events responsible for the two stages have yet to be completely defined. It is now known that initiation usually involves primary damage to DNA, leading to a critical mutation; while promotion involves proliferation and subsequent steps allowing expression of oncogenicity through acquisition of other changes, which are either genetic or epigenetic (Foulds 1954; Hanahan and Weinberg 2000).

Numerous difficulties were identified with the initiation-promotion model (Cohen 1998b; Cohen and Ellwein 1991). A more definitive model of carcinogenesis, incorporating the concepts of time, genetics, and multiple stages, was postulated by Knudson (1971) based on his investigation of retinoblastoma in children. This model led to the concept of tumor suppressor genes. Utilizing DNA damage and increased cell proliferation (the two fundamental precepts set forth in Knudson’s model), Moolgavkar and Knudson (1981) and Greenfield, Ellwein, and Cohen (1984) developed more generalized models based on epidemiologic and animal studies, respectively. J. Weisburger and Williams (1981) also distinguished two classes of carcinogens: genotoxic (more specifically, DNA reactive) and nongenotoxic. Cohen and colleagues have shown that the common factor for the nongenotoxic carcinogens is increased cell proliferation. Although not precisely correct (Cohen and Ellwein 1991), many have used the term “initiator” interchangeably with genotoxic carcinogen and “promoter” with nongenotoxic (non-DNA reactive) carcinogen.

The current carcinogenicity bioassay owes much to lessons learned from the NTP bioassay program originally developed at the National Cancer Institute (NCI). In establishing this program, a key consideration was that because chemically induced tumors are relatively rare, rather than use very large numbers of animals, the maximum dose should be the highest tolerated by the animals (see Haseman 1984), a natural conclusion from the relationship established by Druckrey (1967). The early studies were designed to determine whether industrial chemicals, with structural similarities to established rodent carcinogens such as 2-acetylaminofluorene (2-AAF) and benzo[*a*]pyrene (B[*a*]P), were carcinogenic (E. Weisburger 1983). The majority of such chemicals did prove to be carcinogenic.

From the late 1960s to mid 1970s, on the assumption that most carcinogens were DNA-reactive, considerable effort was spent in developing reliable, short-term tests of genotoxicity. The most significant outcome of this effort was the Salmonella bacterial mutation assay (Ames et al. 1973). It was initially believed that tests such as this could predict most carcinogens. Indeed, as the majority of chemical carcinogens identified up to that time were potent, DNA-reactive compounds, the Ames test was > 90% predictive. The concept was clearly stated in the title of a manuscript by Ames et al. (1973): “Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection.” Reflecting the views of a number of scientists at the time, in another paper Ames (1973) stated, “We . . . suggest that the combined bacteria/liver system be used as a simple procedure for carcinogen detection.”

As the number and chemical diversity of those chemicals tested within programs such as the NTP increased, a range of chemicals with no structural similarities to known DNA-reactive carcinogens and negative in the Ames assay were found to be carcinogenic, the proportion of these that were positive for carcinogenic activity in rats and mice being similar to that for DNA-reactive compounds. However, the tumor profile obtained with these chemicals differed (Fung, Barrett, and Huff 1995). It subsequently became apparent that many of these

chemicals caused cancer by mechanisms that did not involve direct reactivity with DNA, and, indeed, they were negative in short-term tests of genotoxicity. It is now known that there are a number of mechanisms by which a chemical can increase tumor incidence in rats and mice in addition to genotoxicity (MacDonald and Scribner 1999).

In general, such nongenotoxic carcinogens act by increasing DNA replications in the pluripotential cells of a tissue, either by increasing cell proliferation and/or by inhibiting apoptosis (Cohen and Ellwein 1990, 1991; Greenfield, Ellwein, and Cohen 1984; Moolgavkar and Knudson 1981). This increases the probability of producing or selecting cells that develop spontaneous errors or of damage induced by primary initiators or secondary mediators such as reactive oxygen species (Ames and Gold 1997; Cohen 1998a). Hence, although many nongenotoxic carcinogens may act through mechanisms that include a DNA damage component (Klein and Klein 1984), a biological threshold for the carcinogenic response to such compounds will exist (Butterworth and Bogdanffy 1999). To induce the production of a secondary genotoxic species, the nongenotoxic carcinogen still has to achieve a threshold concentration to trigger the precipitating biological event, such as cytotoxicity or inflammation (Butterworth and Bogdanffy 1999; Cohen and Ellwein 1991). This contrasts with genotoxic carcinogens for which, at least in theory, there is the potential of a linear, nonthreshold response (U.S. Environmental Protection Agency [EPA] 2005), although a number of groups are strongly challenging this assumption (e.g., Hoshi et al. 2004; Swenberg et al. 2002; Williams, Iatropoulos, and Jeffrey 2004).

The current testing strategy for carcinogenic potential is based on a dual approach:

1. assessment of genotoxic potential and
2. assessment of carcinogenic potential in the lifetime bioassay in rats and mice.

The results from such studies may be supported by other investigations to determine the mode of action (MOA) and its relevance to humans (dose, metabolism, etc.). Such studies have shown that for those compounds that cause cancer by a nongenotoxic MOA, it is usually a secondary consequence of another toxicological perturbation, such as inflammation or cytotoxicity (Cohen et al. 2004; Sonich-Mullin et al. 2001). Indeed, there is evidence that under the right circumstances, almost any agent can cause cancer in experimental animals (Ashby and Purchase 1993; Norton 1981). A key consideration in this respect is that the high doses necessarily used in the cancer bioassay often cause effects unrelated to those observed at lower doses (MacDonald and Scribner 1999). Effects seen under such circumstances often have no relevance to the assessment of human risk.

As knowledge of MOAs of nongenotoxic carcinogens has increased, three concepts have emerged:

1. A number of MOAs for carcinogenicity are rodent-specific.

2. Tumors occur at detectable incidences at the same, and often only at higher, doses than the primary toxicological perturbation.
3. There is a biological threshold for carcinogens with such MOAs.

As a consequence of the above, there is increasing concern that the current cancer bioassay in the rat and mouse in which compounds are tested at up to the maximum tolerated dose is not very predictive of the potential for human carcinogenicity, and in particular that it has a high false positive rate (Alden et al. 1996; Cohen 2004; Ennever and Lave 2003; Gaylor 2005; Rhomberg et al. 2007; Van Oosterhout et al. 1997). Compounds that are carcinogenic as a consequence of direct reactivity with DNA are now identifiable in short-term tests for genotoxicity (Kirkland et al. 2005). Hence, the majority of compounds subject to a cancer bioassay today that give a positive result act by a nongenotoxic mechanism. Many regulatory authorities will permit exposure to compounds, albeit usually for less than a lifetime, that are negative in an adequate range of genotoxicity tests (U.S. Food and Drug Administration [FDA] 1996). This implies that the bioassay is currently required to identify only those compounds that can cause cancer by a nongenotoxic mechanism. In part, the unreliability of the bioassay in rats and mice is due to the existence of rodent-specific mechanisms of carcinogenicity or responsiveness at very high doses via mechanisms not occurring at lower doses.

Advances in both genotoxicity testing and in biomedical sciences justify a critical reevaluation of the need for the cancer bioassay, or even the proposed genetically engineered mouse alternatives (MacDonald et al. 2004), and whether these tests can be replaced by a more systematic, mechanistically based approach. Currently, use of the bioassay results in risk communication problems, requires consumption of significant development costs, and is a difficult system in which to apply advances in biomedical science. Often, these mechanistic research approaches are used only retrospectively to explain false positives, not prospectively to help in evaluation. During product development, it is the elimination of compounds with the potential to cause cancer that is of primary concern, rather than whether they will definitively produce tumors if given for a lifetime. Hence, an important goal is the development of an efficient, reliable, and cost-effective means of assessing human carcinogenic *potential*, rather than carcinogenesis *per se*, recognizing that some compounds may be abandoned because they are considered potential carcinogens even though this endpoint may not be realized over a lifetime of exposure. However, any such system would have to reliably identify those compounds that would be carcinogenic over a lifetime (low false negative rate), while also having a low false positive rate to ensure cost-effectiveness.

The Health and Environmental Sciences Institute (HESI) established a project to explore the feasibility of such an approach. This was based on developments in the analysis of MOA for chemical carcinogenesis and its human relevance

primarily by the International Life Sciences Institute (ILSI) and the International Programme on Chemical Safety (IPCS) (Boobis et al. 2006; Meek et al. 2003; Sonich-Mullen et al. 2001). An MOA is characterized by a series of key events, which are the biological processes occurring on the causal path to cancer. Qualitative and quantitative consideration of these key events between experimental animals and humans enables conclusions to be reached about human relevance of the carcinogenic effect of the chemical. The ultimate objective of the HESI initiative was to test a strategy in which compounds are evaluated for carcinogenic potential in rats and mice after exclusion of those that are genotoxic or immunosuppressive as determined in relevant tests routinely undertaken in hazard identification and characterization on the premise that such compounds are known often to possess carcinogenic potential (Cohen 2004). Compounds negative for such effects would be evaluated in subchronic tests (initially thirteen-week studies) for the induction of key events associated with known MOAs for carcinogenicity, which should then be predictive of carcinogenic potential in rats and mice. The human relevance of the MOA would then need to be evaluated.

In this study, the NTP database was evaluated for all compounds that were positive for liver, kidney, or lung tumors over the period 2000 to 2005. This database was selected because it contains comprehensive data on both chronic and thirteen-week studies in rats and mice, is publicly accessible, and is among the most comprehensive available. The period 2000 to 2005 was chosen because, prior to this time, the information available was not comprehensive, precluding full evaluation of the compounds. The target tissues were those most commonly showing a tumorigenic response in rats and mice.

The reliability of short-term tests of genotoxicity to detect genotoxic carcinogens was critically evaluated, that is, it was necessary to establish the confidence that could be placed in a negative response and where the weaknesses were, if any. Precursor effects were sought for nongenotoxic carcinogenicity in subchronic tests (thirteen weeks). As part of this exercise, MOAs for which there were no suitable conventional endpoints would be identified. Potentially suitable endpoints to cover these deficiencies that, if possible, could be assessed in conventional subchronic studies, would be identified. These studies would enable the false negative rate to be determined, that is, those compounds for which no relevant key events could be identified. In a subsequent stage it would be necessary to establish the false positive rate, where the occurrence of key events was not accompanied by a carcinogenic response. Analysis of the key events and carcinogenic response would test the hypothesis that protection against such effects would be adequately protective against carcinogenicity and that by understanding the key events, it would be possible to determine human relevance. Ultimately, it is hoped that the results of such studies will enable the development of a science-based, hierarchical approach to assessing the carcinogenic potential of compounds.

The current study was designed to test the hypothesis that the signals of importance for human cancer hazard identification can be detected in shorter-term studies, rather than routinely relying on data from two-year cancer bioassays in rats and mice.

## II. METHODS

The HESI Cancer Hazard Identification Strategies (CHIS) Project Committee elected to use the NTP database in this study because it constitutes the most comprehensive, accessible repository of matching subchronic and long-term information on both pathology and other endpoints, for example, clinical chemistry, available to the participants. The Project Committee was greatly assisted in interrogating the database by scientists from the NTP.

The period 2000 to 2005 was evaluated. Prior to 2000, the NTP database does not contain comprehensive information on all aspects of hazard relevant to the project objectives. Hence, only those reports from the beginning of the year 2000 were considered for evaluation. The study was based solely on the tumorigenicity and genotoxicity data available in the NTP database for the chosen compounds, although some slides from male kidneys in the thirteen-week studies were reviewed (see below). Additional literature searches were not conducted.

Compounds in the NTP database were queried for carcinogenic effects in at least one "cell" of the bioassay, that is, male or female mice or male or female rats, in liver, kidney, or lung. These tissues/organs were selected for study as they are by far the most common targets for carcinogenicity of chemicals in rats and mice. Sixteen chemicals were identified on this basis. Only studies in Fisher 344 (F344/N) rats and/or B6C3F1 mice were included in the analysis because these two strains were most frequently used by NTP during that period. A customized, defined query tool (Excel spreadsheet) was developed by the CHIS Project Committee to assist with searching and recording the results of subchronic (thirteen weeks) rat and mouse toxicity studies for each of the sixteen carcinogenic compounds identified from the two-year rodent bioassay database. Teams of scientists (the authors) reviewed thirteen-week data and data from mutagenicity assays for the sixteen chemicals, with the objective of identifying early signals of carcinogenic potential, for example, cytotoxicity, hyperplasia, and local irritation. Peer reviewers checked the data recorded. Some peer reviewers were CHIS Project Committee participants; others were not. In all cases, the peer reviews were independent of the query exercise.

Table 1 shows the chemicals identified in the NTP database that were found to produce tumors in one or more of the target organ systems and in one or both of the species tested. To obtain some information on false positives as well as false negatives, the histomorphologic findings from thirteen-week studies were examined for all sixteen compounds for all target tissues, including those without evidence of tumors in two-year studies.

TABLE 1.—Evidence of genotoxicity or tumors for National Toxicology Program (NTP) chemicals selected for study in the Health and Environmental Sciences Institute (HESI) Cancer Hazard Identification Strategies (CHIS) project.

Chemical	Route	Genotoxic <sup>a</sup>	Tumors <sup>b</sup>		
			Liver	Kidney	Lung
Anthraquinone (NTP 2005a)	Diet	Positive	Yes (fm, mm, fr, mr)	Yes (fr, mr)	No
Benzophenone (NTP 2006)	Diet	Negative	Yes (fm, mm)	Yes (mr)	No
Decalin (NTP 2005b)	Inhalation	Equivocal ( <i>in vivo</i> )	No	Yes (mr)	No
Elmiron (sodium pentosan-polysulfate) (NTP 2004a)	Gavage	Negative	Yes (hem) <sup>c</sup> (fm, mm)	No	No
Fumonisin B <sub>1</sub> (NTP 2001a)	Diet	Positive (not NTP data)	Yes (fm)	Yes (fr*, mr)	No
Gallium arsenide (NTP 2000a)	Inhalation	Negative	Yes <sup>d</sup> (fr)	No	Yes (fr)
Indium phosphide (NTP 2001b)	Inhalation	Equivocal ( <i>in vivo</i> )	Yes (fm, mm, fr, mr)	No	Yes (fm, mm, fr, mr)
Methyleugenol (NTP 2000b)	Gavage	Negative	Yes (fm, mm, fr, mr)	Yes (mr)	No
2-Methylimidazole (NTP 2004d)	Diet	Positive ( <i>in vivo</i> )	Yes (fm, mm, fr**, mr**)	No	No
o-Nitrotoluene (NTP 2002a)	Diet	Equivocal	Yes (fm, fr, mr)	No	Yes (mr)
Oxymetholone (NTP 1999)	Gavage	Negative	Yes (fr)	No	Yes (fr)
Propylene glycol mono-t-butyl ether (NTP 2004b)	Inhalation	Negative	Yes (mr**)	No	No
Riddelline (NTP 2003)	Gavage	Positive ( <i>in vitro</i> )	Yes (hem) <sup>b</sup> (mm, fr, mr)	No	Yes (fm)
Triethanolamine (NTP 2004c)	Skin	Negative	No	No	No
Urethane (NTP 2004e)	Water	Positive	Yes (fm, mm)	No	Yes (fm, mm)
Vanadium pentoxide (NTP 2002b)	Inhalation	Negative	No	No	Yes (fm, mm, mr)

<sup>a</sup> “*In vivo*” or “*in vitro*” is added when the conclusion is based only on either type of data, not on both.

<sup>b</sup> Species in which tumors appear: fm = female mouse; mm = male mouse; fr = female rat; mr = male rat.

<sup>c</sup> hem = hemangiosarcomas were induced, in addition to hepatocellular tumors.

<sup>d</sup> From Allen et al. (2004).

\* Not statistically significant.

\*\* Equivocal.

### III. GENOTOXICITY

#### A. Methods

For the sixteen chemicals in Table 1, genotoxicity data were obtained from the NTP database, summarized, and evaluated. An overall call for genotoxic, not genotoxic, or equivocal was assigned based on all the test data. A summary table (Table 2) indicates potential *in vitro/in vivo* genotoxicity (“calls” for interpretation for each test), gives an overall evaluation based on weight of evidence, and includes an analysis for structural alerts for genotoxicity based on criteria published by Ashby and Purchase (1993).

#### B. Results (Table 2)

In seven cases, data were available for at least three tests (Ames, *in vitro* chromosome aberrations, and *in vivo* micronucleus). More recently, the NTP strategy is to use the Ames test and the *in vivo* micronucleus assay, which are seen as a more definitive assessment of genotoxicity because of the high false positive incidence in the *in vitro* mammalian cell assays (e.g., Kirkland et al. 2005; Matthews et al. 2006). The micronucleus measurement was typically made on blood samples from the three-month study; for five chemicals, there were also data from an “acute” three-day study, usually in bone marrow. Indium phosphide had only *in vivo* micronucleus data. There were no data for Fumonisin B<sub>1</sub> in the NTP database, and a brief literature review was done. (Only NTP data were considered for the others.)

In three cases, the “call” used by NTP for *in vivo* micronucleus data was questioned, that is, the NTP criteria did not appear to take into account historical ranges for micronucleus data:

Indium phosphide was considered to be negative by NTP; the present authors considered it equivocal because the level of micronucleated polychromatic erythrocytes (MN-PCE) increased from 1.7 in controls to 4.11 in treated females, with a lesser increase in micronucleated normochromatic erythrocytes (MN-NCE).

Propylene glycol mono-t-butyl ether was considered a weak positive in female mice by NTP; the authors of this article considered it negative because the maximum level of micronuclei seen in females was in the range of concurrent (male) and historical controls for the data set examined.

Decalin was considered a weak positive in male and negative in female by NTP; the present authors considered it equivocal or negative overall, again because the maximum level of micronuclei seen was in the range of historical controls for the data set examined.

In some cases, the data from the *in vitro* chromosome aberration test were not considered conclusive because the protocol used had only one “early” sampling time, for example, 10.5 to 13 hours, and it is known that it is more reliable to sample at about 20 hours, as recommended in regulatory guidelines such as those of the Organisation for Economic Cooperation

TABLE 2.—Summary of structural alerts and findings for genotoxicity tests conducted for sixteen National Toxicology Program (NTP) chemicals with positive tumor findings.

Chemical	Structural Alert	Genotoxicity findings <sup>a</sup>			Comments
		Salmonella	Mammalian		
			<i>In vitro</i>	<i>In vivo</i>	
Anthraquinone (NTP 2005a)	–	P	No data	P	Genotoxic. Note that the NTP carcinogenicity study used a batch of anthraquinone contaminated with a known mutagen (9-nitroanthracene).
Benzophenone (NTP 2006)	–	N	No data	N	Not genotoxic.
Decalin (NTP 2005b)	–	N	No data	W-P in M; N in F; (E)	Equivocal <i>in vivo</i> data; requires more information, as chemical is not genotoxic <i>in vitro</i> .
Elmiron (NTP 2004a)	–	N	No data	N	Not genotoxic.
Fumonisin B <sub>1</sub> (NTP 2001a)	–	No data	No data	No data	Genotoxic. Published data: P micronucleus assay <i>in vitro</i> and <i>in vivo</i> ; P SCE and W-P chromosome aberrations <i>in vitro</i> ; N UDS <i>in vitro</i> .
Gallium arsenide (NTP 2000a)	n/a	N	No data	N	Not genotoxic.
Indium phosphide (NTP 2001b)	n/a	No data	No data	N (E)	Minimal data but equivocal <i>in vivo</i> .
Methyleugenol (NTP 2000b)	+←	N	N <sup>b</sup>	N	Not genotoxic.
2-Methylimidazole (NTP 2004d)	–	N	No data	P	Positive <i>in vivo</i> . Requires more information as the chemical is not genotoxic <i>in vitro</i> .
o-Nitrotoluene (NTP 2002a)	+←	N	N <sup>b</sup>	E; E in M; N in F	Equivocal genotoxicity.
Oxymetholone (NTP 1999)	–	N	N	N	Not genotoxic.
Propylene glycol mono-t-butyl ether (NTP 2004b)	–	N	N	W-P in F (N)	Not genotoxic.
Riddelliine (NTP 2003)	+←	P	P	N	Genotoxic.
Triethanolamine (NTP 2004c)	–	N	N <sup>b</sup>	N	Not genotoxic.
Urethane (NTP 2004e)	+←	P	N <sup>b</sup>	P	Genotoxic.
Vanadium pentoxide (NTP 2002b)	n/a	N	No data	N	Not genotoxic.

<sup>a</sup> NTP call; overall call by Health and Environmental Sciences Institute (HESI) committee based on weight of evidence appears in parentheses; P = positive; N = negative; E = equivocal; W-P = weak positive; M = male; F = female; n/a = not available.

<sup>b</sup> *In vitro* aberration assay negative but potentially suboptimal protocol because of harvest time (ten to thirteen hours). *In vitro* sister chromatid exchange (SCE) assay positive.

and Development (OECD) and the International Conference on Harmonisation (ICH) (see also Bean, Armstrong, and Galloway 1992; Galloway et al. 1994). This is not likely to affect the overall conclusions.

The data for anthraquinone are considered suspect because other carcinogenicity studies were negative, and the NTP carcinogenicity study used a batch of anthraquinone contaminated with the potent mutagen 9-nitroanthracene at a level of 1,200 ppm (Butterworth, Mathre, and Ballinger 2001). (A purified sample was negative in the Ames test.) Certainly, it can be said that the material used by the NTP was mutagenic (Doi, Irwin, and Bucher 2005).

### C. Discussion/Conclusions

Overall, only three compounds were clearly genotoxic (that is, 2-methylimidazole, riddelliine, and urethane), in addition to anthraquinone. One of these was called positive based on *in vivo* data (i.e., 2-methylimidazole), but was negative in the Ames test and does not contain a structural alert for genetic toxicity. Eight were not genotoxic, three were equivocal, and one had no NTP data (Fumonisin B<sub>1</sub>) but has been shown to be positive in a micronucleus assay *in vivo* (Aranda et al. 2000) and *in vitro* (Lerda et al. 2005). The published Ames test data are considered inadequate due to the low dose tested and

the use of only three strains of Salmonella. Weak positive results for chromosome aberrations and a positive sister chromatid exchange (SCE) test were reported by Lerda et al. (2005), and a negative *in vitro* unscheduled DNA synthesis (UDS) assay was reported by.

Of the nongenotoxic conclusions, four were based on data from two tests (Ames and *in vivo* micronucleus), and the other four were based on the results of three tests.

Of the equivocal conclusions, three were based on equivocal *in vivo* data. Indium phosphide had no *in vitro* data and equivocal *in vivo* data, and decalin and o-nitrotoluene had negative Ames data and equivocal *in vivo* data. 2-Methylimidazole was also positive *in vivo* but not in the Ames test; *in vitro* cytogenetics data would be of value here.

It is unusual to find positive results *in vivo* when *in vitro* assays are negative. A known confounding factor of *in vivo* micronucleus assays in hematopoietic cells is disturbance of erythropoiesis. Regenerative anemia following bleeding or chemical treatment, stimulation of red blood cell production by erythropoietin, and extramedullary hematopoiesis have been associated with increases in micronuclei in the absence of any treatment with genotoxins (reviewed in Tweats et al. 2007).

An examination of the hematology data from these studies indicates that in some cases regenerative anemia associated



with altered erythropoiesis may have caused a false positive result, that is, one not associated with genotoxicity. Indium phosphide and 2-methylimidazole both had changes including hematopoietic cell proliferation of the spleen; decalin and o-nitrotoluene did not. It is interesting that even anthraquinone had increases in red blood cell proliferation with large increases in circulating reticulocytes. This might explain why increases in micronuclei were seen only after a three-month treatment and not after three daily doses of anthraquinone and points to the difficulty of interpreting results *in vivo* even with a mutagen. The other chemical that was positive *in vivo*—urethane—had no hematology data reported.

Other possible explanations for *in vivo* micronucleus induction by compounds that do not induce mutations in the Ames test *in vitro* include (1) differences in metabolism *in vivo* versus *in vitro*; and (2) induction of micronuclei that represent chromosome loss and the potential for aneuploidy, that is, the mechanism involves disturbances of chromosome segregation and not DNA reactivity.

For complete transparency, all sixteen compounds, regardless of genotoxicity results, were included in the tabular presentations of data in this study.

#### IV. IMMUNOSUPPRESSIVE ACTIVITY

##### A. Methods

The NTP database was searched for clinical and anatomical pathology findings related to disorders of the immune system, including evidence of downregulation (possible immune suppression) and proliferation. The database was also searched for any evidence of neoplasia related to elements of the immune system.

Data were obtained from subchronic studies (thirteen weeks) in F344 rats and B6C3F1 mice for all sixteen compounds derived from the NTP database (Table 1). Findings included changes in hematology (total leukocyte, segmented neutrophil, lymphocyte, and monocyte counts); changes in spleen and/or thymus weights; and histopathological findings in the bone marrow, spleen, thymus, and lymph nodes.

Of the sixteen chemicals evaluated, information for riddelliine, triethanolamine, and Fumonisin B<sub>1</sub> was very limited, and the absence of any effect on the immune system for these three chemicals should be considered with caution.

##### B. Results (Table 3)

There were ten out of sixteen chemicals with changes in one or more data endpoints related to the immune system. Of these ten chemicals, eight chemicals had changes suggesting down-regulation of the immune system, which, in all cases, were likely secondary to significant stress or illness with release of endogenous glucocorticoids. Two chemicals (o-nitrotoluene and Elmiron [sodium pentosanpolysulfate]) caused a slight increase in lymphocyte counts in male and

female rats and the accumulation of vacuolated histiocytes in multiple organs including the lung (see Lung section). It has been suggested that Elmiron may induce a lysosomal disorder that is characterized by histiocytes containing mucins and lipidic material within membrane-bound vacuoles (Nyska et al. 2002).

Gallium arsenide caused contact dermatitis in female mice during a contact hypersensitivity study but no evidence of immunotoxicity in standard toxicity studies. There was an increased incidence of mononuclear cell leukemia in female rats at the end of the two-year carcinogenicity study, with incidences of twenty-two, eighteen, twenty-one, and thirty-three of fifty in the control, low-, mid- and high-dose groups, respectively. This finding was originally considered significant, but this interpretation is debatable. The pathogenesis of this putative increased incidence of mononuclear cell leukemia is uncertain, and it is unlikely related to immunosuppression because the doses used in the two-year studies were significantly (75X) less than the high dose used in the thirteen-week study where there was no evidence of direct immunosuppression (NTP 2000a).

##### C. Discussion/Conclusions

The interest in evaluating immunosuppressive activity is related to the putative protective role of the immune system in development of cancer. Current ICH guidance lists increased incidence of tumors as one of the five signs of possible immunosuppression in short-term toxicity studies (ICH 2005). The relationship between immunosuppression and cancer is still under investigation, and immunosuppression is currently linked to neoplasia mostly related to infectious agents. In humans, these include Epstein-Barr virus, human herpes virus-8, hepatitis B and C viruses, human papilloma viruses, and *Helicobacter pylori*. Populations most studied for immunosuppression-related neoplasia are HIV/AIDS patients and organ transplant recipients subject to aggressive immunosuppressive therapy and individuals with inherited immunodeficiencies. Interestingly, the types of cancer differ between the two groups, with HIV/AIDS patients more likely to acquire Hodgkin lymphoma, non-Hodgkin lymphoma, Kaposi sarcoma, and anal cancer. Conversely, transplant recipients have much higher standardized incidence ratios than HIV/AIDS patients for several cancers, including malignancies of the vulva and vagina (Grulich et al. 2007; Serraino et al. 2007).

Of the sixteen chemicals reviewed, none caused direct immunosuppression in thirteen-week studies in rats and mice. Many chemicals (eight/sixteen) caused down-regulation of the immune system by one or more standard endpoints in subchronic studies, but in all instances, these were attributed to stress. There were no instances where chemicals that did not show any evidence of immunosuppression in subchronic studies were subsequently tested in a specific immunotoxicity study.

TABLE 3.—Immunotoxicologic findings in rats and mice following subchronic exposure to National Toxicology Program (NTP) chemicals selected for study in the Health and Environmental Sciences Institute (HESI) Cancer Hazard Identification Strategies (CHIS) project.

Chemical	Species/ gender (M = male; F = female)	Clinical pathology <sup>a</sup>	Organ weights <sup>b</sup>	Histopathology, immune system	Effect on immune system	Immunotoxicity studies
Anthraquinone (NTP 2005a)	Rat M,F Mouse M,F	Negative	Negative	Hematopoietic cell proliferation in spleen; hyperplasia in bone marrow	Negative	Not performed
Benzophenone (NTP 2006)	Rat M,F Mouse M,F	Negative	↓ Thymus	Atrophy in bone marrow (rat); atrophy in thymus (mouse); depletion of cellular lymphoid follicles (mouse)	Stress	Not performed
Decalin (NTP 2005b)	Rat M,F Mouse M,F	Negative	Negative	Negative	Negative	Not performed
Elmiron (NTP 2004a)	Rat M,F Mouse M,F	↑ Lymphocytes ↑ Neutrophils— rats	↑ Spleen	Cellular infiltration of histiocytes in spleen, mandibular, and mesenteric lymph nodes	Inflammation	Not performed
Fumonisin B <sub>1</sub> (NTP 2001a)	Rat M,F Mouse M,F	Information not available	Information not available	Information not available	Information not available	Information not available
Gallium arsenide (NTP 2000a)	Rat M,F Mouse M,F	↑ Neutrophils	Negative	Increased hematopoiesis in bone marrow, spleen; increased cellularity in tracheobronchial, mediastinal lymph node and mandibular lymph node	Inflammation	Contact hypersensitivity (+)
Indium phosphide (NTP 2001b)	Rat M,F Mouse M,F	↑ Neutrophils	↓ Thymus	Hyperplasia in bronchial and mediastinal lymph nodes	Stress; inflammation	Not performed
Methyleugenol (NTP 2000b)	Rat M,F Mouse M,F	Negative	↓ Thymus ↓ Spleen	Negative	Stress	Not performed
2-Methylimidazole (NTP 2004d)	Rat M,F Mouse M,F	↑ Lymphocytes	↓ Thymus ↓ Spleen	Negative	Stress	Not performed
o-Nitrotoluene (NTP 2002a)	Rat M,F	↑ Lymphocytes	Negative	Increased hematopoiesis and hemosiderin in spleen	Stress	Not performed
Oxymetholone (NTP 1999)	Rat M,F Mouse M,F	Negative	↓ Thymus	Negative	Stress	Not performed
Propylene glycol mono-t-butyl ether (NTP 2004b)	Rat M,F Mouse M,F	Negative	Negative	Negative	Negative	Not performed
Riddelliine (NTP 2003)	Rat M,F	Information not available	Information not available	Lymph node congestion and hemosiderin pigments	Negative	Information not available
Triethanolamine (NTP 2004c)	Rat M,F Mouse M,F	Information not available	Information not available	Negative	Negative	Information not available
Urethane (NTP 2004e)	Rat M,F Mouse M,F	↓ Leukocytes ↓ Lymphocytes	↓ Thymus	Lymphoid depletion in spleen, thymus, mandibular and mesenteric lymph nodes; cellular depletion of bone marrow	Stress	Mixed results
Vanadium pentoxide (NTP 2002b)	Rat M,F Mouse M,F	↓ Lymphocytes ↑ Neutrophils	↓ Thymus	Lymphoid depletion in spleen, thymus, mandibular and mesenteric lymph nodes; hypocellularity of bone marrow	Stress; inflammation	Not performed

<sup>a</sup> Clinical pathology parameters evaluated were total leukocytes, segmented neutrophils, and lymphocyte and monocyte counts, and are expressed as increase or decrease compared to concurrent control values (↑ = increase; ↓ = decrease).

<sup>b</sup> Organs weighed included thymus and less frequently spleen. Changes are expressed as increase or decrease compared to concurrent control values (↑ = increase; ↓ = decrease).

Current ICH guidance for chemicals supports the view that specific immunotoxicity investigation is not warranted in these situations (ICH 2005).

There was no clear evidence of neoplasia in elements of the immune system.

For complete transparency, all sixteen compounds, regardless of immunosuppressive activity, were included in the tabular presentations of data in this study.

## V. LIVER

### A. Methods

In the subchronic (thirteen-week) toxicity studies, the recorded organ weight, clinical pathology, and histopathology data were reviewed for each compound. These included increased relative liver weight, hepatocellular hypertrophy, altered foci, hepatocyte necrosis, hepatocyte vacuolation,

hepatocyte degeneration, bile duct hyperplasia, increased alanine transaminase (ALT) levels, increased sorbitol dehydrogenase (SDH) levels, and increased bile acid/bilirubin levels. In a similar analysis by Allen et al. (2004), the predictive value of hepatocyte hypertrophy, necrosis, cytomegaly, and increased liver weight in subchronic studies was investigated. In this study, the authors concluded that these four criteria detected 100% of potential liver carcinogens; however, the detection rate included several false positives.

#### B. Results (Table 4)

For the sixteen chemicals in our evaluation, thirteen were recorded as rodent liver carcinogens (for which increased incidences of hepatocellular adenomas and/or carcinomas occurred, except where footnoted) (either rat [male/female] or mouse [male/female] or both species). For each sex and each species, the tumor outcome, histopathologic changes, significant clinical pathology, and increased relative liver weight are illustrated.

Increased relative liver weight was recorded for at least one sex of one species (rat/mouse) from the thirteen-week NTP toxicity studies in ten of thirteen positive liver carcinogenic compounds. Other single endpoints at thirteen weeks were associated less frequently with tumor outcomes. These included (in at least one sex of one species) hepatocellular hypertrophy or increased bile acids for five of thirteen carcinogens, hepatocellular necrosis or increased ALT levels for four of thirteen carcinogens, hepatocellular vacuolation/degeneration for three of thirteen carcinogens, and altered foci or increased SDH levels for two of thirteen carcinogens.

Association with tumor outcome was strengthened by grouping together thirteen-week toxicological endpoints. Combining the presence of hepatocellular hypertrophy and/or necrosis with increased relative organ weight demonstrated an association with twelve of thirteen liver chemical carcinogens for at least one sex of one species of the NTP bioassay. This increased predictive rate is similar to the results of the previous retrospective study (Allen et al. 2004) (see Liver Discussion section below).

When positive tumor outcomes were collectively considered for both sexes of both species of the cancer bioassay for this particular set of thirteen liver carcinogens, no false positives were recorded. Therefore, if liver-associated changes were observed in any sex/species from the thirteen-week studies, there were always tumors apparent in one of the long-term bioassays.

However, several false positives occurred if single associations are considered between one sex and one species. For example, the male and female rat exposed to benzophenone demonstrated no treatment-related liver tumor response, but in the thirteen-week studies there was increased relative liver weight, an increased incidence of hepatocellular hypertrophy and vacuolation, increased bile acids, and increased SDH levels. Likewise, Elmiron, while inducing increased relative organ weight and hepatocellular

vacuolation in the male rat at thirteen weeks, did not induce an increased incidence of liver tumors after two years of treatment.

Similarly, when positive tumor outcomes are collectively considered for both sexes and both species of the cancer bioassay for these thirteen liver carcinogens, only one false negative was apparent. Inhalation exposure to indium phosphide resulted in liver tumors in the male and female mouse long-term bioassay, while there were no changes observed at thirteen weeks.

#### C. Discussion

Increased relative liver weight, histopathological changes, and increases in clinical pathology parameters in rat and/or mouse thirteen-week subchronic toxicity studies in the NTP database were positively associated with the majority of tumorigenic outcomes. As mentioned above, this concurs with a previous retrospective study using the NTP database (Allen et al. 2004).

Similar to the set of thirteen liver carcinogens examined here, Allen et al. (2004) demonstrated that an increased liver weight was associated with eight of eleven rat liver carcinogens. When considered as separate entities, hepatocellular hypertrophy identified five of eleven carcinogens, and hepatocellular necrosis identified four of eleven carcinogens. Pooling/grouping hepatocyte hypertrophy + necrosis + cytomegaly + increased liver weight identified eleven of eleven liver carcinogens.

Likewise, in another retrospective review of nine nongenotoxic NTP carcinogens, increased relative liver weight was the most highly specific predictor of mouse liver tumors (Elcombe et al. 2002). It has also been noted by the U.S. EPA (2002) that when hepatocellular hypertrophy (and corresponding increased liver size/weight) is accompanied by another more severe toxic change (e.g., clinical pathology changes/other histopathology changes), the combination of these changes may reflect underlying carcinogenic potential in rats and mice.

#### D. Conclusions

Conventional mammalian toxicological endpoints identified at thirteen weeks are associated with most tumor outcomes as mentioned above, but these indicators produce a number of false positives for compounds tested in the overall NTP database. Conventional endpoints such as increased relative liver weights and corresponding hepatocellular hypertrophy often represent temporal adaptations that demonstrate reversibility upon withdrawal of treatment. In future studies, it will be important to analyze the magnitude and dose response for these effects to determine whether predictivity can be improved. One chemical, indium phosphide, was a false negative on the basis of an absence of any treatment-related, conventional liver changes for male and female mice at thirteen weeks (as similarly reported by Allen et al. 2004). (Note: Supporting evidence for this chemical compound's tumorigenic response in the

TABLE 4.—Positive hepatocellular tumor outcomes from National Toxicology Program (NTP) two-year rodent bioassays, with preneoplastic liver toxicological endpoints from corresponding subchronic (thirteen-week) toxicity studies in the mouse and rat.

Chemical	Female mouse	Male mouse	Female rat	Male rat
Anthraquinone (NTP 2005a)	↑ Relative organ weight Hypertrophy <b>Tumors</b>	↑ Relative organ weight Hypertrophy <b>Tumors</b>	↑ Relative organ weight Hypertrophy Bile acid <b>Tumors</b>	↑ Relative organ weight Hypertrophy <b>Equivocal tumors</b>
Benzophenone (NTP 2006)	↑ Relative organ weight Hypertrophy Bile acid ↑ ALT, ↑ SDH <b>Tumors</b>	↑ Relative organ weight Hypertrophy Bile acid ↑ ALT, ↑ SDH <b>Tumors</b>	↑ Relative organ weight Hypertrophy Vacuolation Bile acid ↑ SDH	↑ Relative organ weight Hypertrophy Vacuolation Bile acid
Decalin (NTP 2005b)	↑ Relative organ weight	↑ Relative organ weight	↑ Relative organ weight	↑ Relative organ weight
Elmiron (NTP 2004a)	↑ Relative organ weight Vacuolation <b>Tumors<sup>a</sup></b>	↑ Relative organ weight Vacuolation <b>Tumors<sup>a</sup></b>	↑ Relative organ weight	↑ Relative organ weight Vacuolation
Fumonisin B <sub>1</sub> (NTP 2001a) (28-day study)	Hypertrophy Necrosis Bile duct hyperplasia <b>Tumors</b>	No treatment-related liver changes	No treatment-related liver changes	(Allen et al. 2004) Degeneration Bile duct hyperplasia (28-day study) <b>Tumors</b>
Gallium arsenide (NTP 2000a)	No treatment-related liver changes	No treatment-related liver changes	“Clear evidence of carcinogenicity” (Allen et al. 2004) ↑ Organ weight (Allen et al. 2004) <b>Tumors</b>	↑ ALT
Indium phosphide (NTP 2001b)	<b>Tumors</b>	<b>Tumors</b>	(Allen et al. 2004) Necrosis <b>Tumors</b>	(Allen et al. 2004) Necrosis ↑ ALT Bile acid <b>Tumors</b>
Methyleugenol (NTP 2000b)	↑ Relative organ weight Necrosis Bile duct hyperplasia <b>Tumors</b>	↑ Relative organ weight Necrosis Bile duct hyperplasia <b>Tumors</b>	↑ Relative organ weight Hypertrophy Bile duct hyperplasia ↑ ALT Bile acid <b>Tumors</b>	↑ Relative organ weight Hypertrophy Bile duct hyperplasia ↑ ALT Bile acid <b>Tumors</b>
2-Methylimidazole (NTP 2004d)	<b>Tumors</b>	↑ Relative organ weight <b>Tumors</b>	Liver enzyme <b>Equivocal tumors</b>	Liver enzyme <b>Equivocal tumors</b>
o-Nitrotoluene (NTP 2002a)	↑ Relative organ weight <b>Tumors</b>	↑ Relative organ weight	↑ Relative organ weight Bile acid <b>Tumors</b>	↑ Relative organ weight Vacuolation ↑ ALT Bile acid <b>Tumors</b>
Oxymetholone (NTP 1999)	No treatment-related liver changes	No treatment-related liver changes	↑ Relative organ weight <b>Tumors</b>	No treatment-related liver changes
Propylene glycol mono- <i>t</i> -butyl ether (NTP 2004b)	No treatment-related liver changes	No treatment-related liver changes	↑ Relative organ weight	↑ Relative organ weight <b>Equivocal tumors</b>
Riddelliine (NTP 2003)	↑ Relative organ weight Hypertrophy	↑ Relative organ weight Hypertrophy <b>Tumors<sup>a</sup></b>	↑ Relative organ weight Hypertrophy Necrosis Altered foci Nodular hyperplasia Bile duct hyperplasia ↑ SDH <b>Tumors<sup>a</sup></b>	Hypertrophy Necrosis Altered foci Bile duct hyperplasia <b>Tumors<sup>a</sup></b>
Triethanolamine (NTP 2004c)	[Inadequate study (Allen et al. 2004)]— <i>Helicobacter</i> infection ↑ Relative organ weight	[Inadequate study (Allen et al. 2004)]— <i>Helicobacter</i> infection ↑ Relative organ weight	No treatment-related liver changes	No treatment-related liver changes
Urethane (NTP 2004e)	Altered foci <b>Tumors</b>	Altered foci <b>Tumors</b>	↑ Relative organ weight Vacuolation/degeneration Altered foci	↑ Relative organ weight Vacuolation/degeneration Altered foci Bile acid
Vanadium pentoxide (NTP 2002b)	No treatment-related liver changes	No treatment-related liver changes	No treatment-related liver changes	No treatment-related liver changes

<sup>a</sup> Hemangiosarcoma.

mouse was demonstrated by increased incidences of nonneoplastic eosinophilic foci in a dose-response relationship [for both sexes], as compared to controls, at the two-year time point [as described in the NTP report].

The authors conclude that conventional liver endpoints currently identified in subchronic (thirteen-week) toxicity studies in rats and mice are not adequate to identify all chemicals with carcinogenic potential.

Additional endpoints may identify other key events that might more accurately predict carcinogenic potential in rats and mice. These key events, in turn, will enhance analysis for defining MOAs to better assess human carcinogenic potential/risk. Specifically, these endpoints include increases in cell proliferation (S-phase response) and induction/inhibition of apoptosis (measurement of labeling indices for both events), constitutive androstane receptor (CAR) nuclear receptor activation (reporter assays), cytochrome P450 induction (direct biochemical measurement), and peroxisome proliferation (measurement of palmitoyl coenzyme A oxidase activity). Such key precursor events could be measured in short-term investigative studies, using three-, seven-, fourteen-, twenty-eight-, and/or ninety-day exposure scenarios.

Further key indicators may be identified from the variety of developing -omics technology platforms, particularly as MOA studies expand into exploring genomic signatures and pathway mapping associated with commonly accepted key events, including CAR activation and peroxisome proliferation.

## VI. KIDNEY

The renal tumors referred to in this section are of renal tubular origin. The histologic changes are indicators of tubule injury or change.

### A. Methods

Five of the sixteen chemicals identified in the NTP database produced tumors in the rat kidney. No kidney tumors were induced in mice. Four of these chemicals (benzophenone, decalin, Fumonisin B<sub>1</sub>, methyleugenol) produced kidney tumors only in the male rat, not in the female. Anthraquinone produced tumors in both the female and male rat.

Initial evaluation for assessment of renal alterations after thirteen weeks of study included parameters that were reported in the histopathology tables by the NTP. The renal alterations and data presented included hyaline droplets, inflammation, chronic progressive nephropathy, and absolute and relative kidney weights. The histopathology evaluation was based on the NTP report, except for Fumonisin B<sub>1</sub>, which was based on results of short-term studies that had been previously published (Dragan et al. 2001; Howard et al. 2001; Voss et al. 1995). Kidney weights for Fumonisin B<sub>1</sub> were not available.

Subsequently, and as part of a concurrent evaluation conducted by the NTP, an author of this article (Dr. Gordon Hard) reviewed the slides from male rat kidneys from thirteen-week studies for most of the sixteen chemicals (except Fumonisin B<sub>1</sub>), including the additional histopathologic indicators of

necrosis/apoptosis, hyperplasia, karyomegaly, vacuolization, tubular basophilia (not associated with chronic progressive nephropathy), and increased mitotic activity. The slides for Fumonisin B<sub>1</sub> were not reexamined during this review because they were not available. However, the slides for Fumonisin B<sub>1</sub> had been reviewed as part of another project (Hard et al. 2001; Bucci et al. 1998).

### B. Results (Table 5)

All four chemicals that produced kidney tumors, and for which data were available regarding kidney weight at the thirteen-week time point (anthraquinone, benzophenone, decalin, methyleugenol), had elevated kidney weights (Table 5), both absolute and relative to body weight. For anthraquinone, kidney weight was elevated in both the female and male rats, and both sexes developed renal tumors. Benzophenone treatment increased kidney weight in both female and male rats, but tumors only occurred in the male. Decalin and methyleugenol increased the kidney weights and caused renal tumors only in male rats.

The kidney findings for all of the chemicals are listed in Table 5. The standard histopathologic criteria for evaluating the kidney resulted in a lack of detection of renal alterations after thirteen weeks of treatment with anthraquinone, benzophenone, decalin, or methyleugenol. There was evidence of regeneration associated with benzophenone and decalin treatment. In contrast, Fumonisin B<sub>1</sub> induced extensive apoptosis, and degenerative and regenerative changes at early time points (Dragan et al. 2001; Howard et al. 2001).

Additional targeted analysis that described renal alterations in greater detail than is typical in the standard NTP report demonstrated that there was a significant increase in renal tissue responses with a number of chemicals including the tumorigens. Hyaline droplets were present in female and male rat kidneys following anthraquinone administration, and decalin treatment in male rats only. Regenerative changes were present in the kidneys from male rats treated with benzophenone and decalin. Chronic progressive nephropathy was increased in female rats treated with anthraquinone to a limited extent but significantly in the male rats treated with anthraquinone. Inflammatory changes were also present in male rats treated with benzophenone and decalin. No changes were seen in the mouse kidneys for the five chemicals producing kidney tumors in rats except for nonspecific cellular alterations in male mice administered decalin.

Of the eleven chemicals evaluated in this study that did not produce kidney tumors, five (urethane, oxymetholone, 2-methylimidazole, propylene glycol t-butyl ether, and indium phosphide) produced alterations in the kidneys after thirteen weeks of treatment. Urethane produced nephropathy (not further defined) in male and female mice and male and female rats. Oxymetholone treatment resulted in an increase in kidney weight in the female mouse and in the female and male rat. In addition, there were regenerative changes in kidneys of the female and male rat administered oxymetholone. No renal lesions were seen in the male mouse treated with

TABLE 5.—Histologic findings in thirteen-week studies with renal tumor outcome in corresponding two-year studies.

Chemical	Female mouse	Male mouse	Female rat	Male rat
Anthraquinone (NTP 2005a)	No renal lesions	No renal lesions	↑ Organ weight <sup>a</sup> Nephropathy Hyaline droplets <b>Tumors</b>	↑ Organ weight Nephropathy Hyaline droplets <b>Tumors</b>
Benzophenone (NTP 2006)	No renal lesions	No renal lesions	↑ Organ weight Casts Regeneration	↑ Organ weight Casts Regeneration <b>Tumors</b>
Decalin (NTP 2005b)	No renal lesions	Cellular alteration	No renal lesions	↑ Organ weight Casts Regeneration Hyaline droplets <b>Tumors</b>
Elmiron (NTP 2004a)	No renal lesions	No renal lesions	No renal lesions	No renal lesions
Fumonisin B <sub>1</sub> (NTP 2001a)	No renal lesions	No renal lesions	Apoptosis Regeneration <b>Tumors</b> (not statistically significant)	Apoptosis Regeneration <b>Tumors</b>
Gallium arsenide (NTP 2000a)	No renal lesions	No renal lesions	No renal lesions	No renal lesions
Indium phosphide (NTP 2001b)	No renal lesions	No renal lesions	No renal lesions	Nephropathy
Methyleugenol (NTP 2000b)	No renal lesions	No renal lesions	No renal lesions	↑ Organ weight <b>Tumors</b>
2-Methylimidazole (NTP 2004d)	Hemosiderin	Hemosiderin	No renal lesions	Nephropathy
o-Nitrotoluene (NTP 2002a)	No renal lesions	No renal lesions	No renal lesions	No renal lesions
Oxymetholone (NTP 1999)	↑ Organ weight Bowman capsule metaplasia	No renal lesions	↑ Organ weight Regeneration Bowman capsule metaplasia	↑ Organ weight Regeneration Mineralization
Propylene glycol mono-t-butyl ether (NTP 2004b)	No renal lesions	No renal lesions	↑ Organ weight Regeneration	↑ Organ weight Regeneration Casts Hyaline droplets
Riddelliine (NTP 2003)	No renal lesions	No renal lesions	No renal lesions	No renal lesions
Triethanolamine (NTP 2004c)	No renal lesions	No renal lesions	No renal lesions	No renal lesions
Urethane (NTP 2004e)	Nephropathy	Nephropathy	Nephropathy	Nephropathy
Vanadium pentoxide (NTP 2002b)	No renal lesions	No renal lesions	No renal lesions	No renal lesions

<sup>a</sup> Increases in organ weights are relative and absolute.

oxymetholone. 2-Methylimidazole treatment resulted in increased nephropathy in the male rat. No renal alterations were present in the female rat, and there were no elevations of kidney weight in either sex of either species. Indium phosphide exposure resulted in chronic progressive nephropathy in both female and male rats. No increase in kidney weight or other kidney findings were found with indium phosphide.

### C. Discussion/Conclusions

Based on this limited sample of chemicals that produced kidney tumors in rats in two-year bioassays, all caused detectable alterations after thirteen weeks of treatment. The feature that consistently gave a positive signal was the nonspecific finding of an increase in kidney weight, both absolute and relative. This is similar to what has been reported for rodent liver carcinogens (Allen et al. 2004). Significantly, all exposure groups that had no effects in the kidney after thirteen weeks of treatment had no renal tumors after two years, and all exposure groups that had tumors after two years had renal alterations at thirteen weeks.

In addition to kidney weight, the additional criteria including changes that indicate cell death (necrosis and/or apoptosis) and evidence of regeneration (basophilia, karyomegaly, mitoses) were not consistently diagnosed in the kidneys that were positive for rodent kidney carcinogens in the standard NTP study report. All of the rodent renal carcinogens could be detected in the thirteen-week assays due to diagnosis of hyaline droplets and increased chronic progressive nephropathy, in addition to the above lesions diagnosed on subsequent review. In this set of studies evaluated, there were no false negatives; however, there were false positives in that some exposures caused renal lesions after thirteen weeks, but no renal tumors in two-year bioassays. Thus, utilizing kidney weight and thorough histologic review of the kidneys after thirteen weeks of treatment detected all of the rodent renal tumorigens in this set of studies. For screening purposes, it is essential that false negatives do not occur.

This screening approach does not directly demonstrate mode of toxic or carcinogenic action, nor does it provide definitive information on likelihood of human carcinogenicity. However, the findings in these short-term studies, combined

with the genotoxicity assessment, can provide helpful clues. For example, for Fumonisin B<sub>1</sub>, the MOA appears to include the key events of stimulation of extensive apoptosis with significant regeneration that could lead to kidney tumors (Dragan et al. 2001). Such an MOA potentially could occur in humans. In contrast, the other four chemicals that induced kidney tumors in the two-year bioassay from the current group of chemicals produced kidney tumors by either an increase in chronic progressive nephropathy or by binding to  $\alpha_{2u}$ -globulin (as indicated by increased hyaline droplets), leading to tubular cytotoxicity, regeneration, and eventually tumors. These two MOAs are detectable in the thirteen-week screening process. However, neither of these MOAs is considered to be relevant for human cancer risk (Dybing and Sanner 1999; Hard, Johnson, and Cohen 2009; Lock and Hard 2004).

## VII. LUNG

### A. Methods

This section reviews data from the NTP database obtained for the sixteen compounds in Table 1 and focuses on and focuses on evidence of histomorphologic alterations of the lung identified in thirteen-week studies in two species (B6C3F1 mice and F344 rats) and the presence or absence of lung tumors in these same species from two-year carcinogenicity studies. This evaluation attempts to draw correlations between the occurrences of pulmonary pathology identified in thirteen-week studies with the subsequent emergence of lung tumors. It is important to note that the routes of exposure are variable among the compounds tested and include dosing by drinking water, feed, and inhalation. Therefore, care must be exercised in interpreting the outcomes of localized intrapulmonary high particle burden versus systemic exposure.

As the purpose of this exercise was to identify signals in thirteen-week studies that might predict tumor generation, the data do not take into account the presence or absence of similar signals of inflammation or hyperplasia identified in the two-year bioassay itself. The analysis is only concerned with the presence of those signals at thirteen weeks under the conditions of that particular study. The lack of a lesion, such as inflammation, at thirteen weeks does not nullify a mechanistic association with the emergence of a tumor—only that it was not detected with these routine evaluations at a time point that would allow such signals to be consistent predictors of subsequent tumor formation. Such a lesion might yet occur at a time beyond thirteen weeks and possibly still be associated with the final tumorigenic outcome. Should this be the case, consideration would need to be given as to how it might be taken into account in developing a cancer hazard identification strategy based on the findings of the present study.

The following diagnostic terms for histomorphologic alterations were used by NTP to describe lung lesions in thirteen-week studies: chronic active inflammation, inflammation NOS (not otherwise specified), alveolar epithelial hyperplasia, bronchiolar hyperplasia, proteinosis, fibrosis, histiocytic infiltration, and foreign body. The following diagnostic terms for

lung tumors were used by NTP in the two-year bioassay studies: alveolar/bronchiolar adenoma, alveolar/bronchiolar carcinoma, alveolar/bronchiolar adenoma or carcinoma, and squamous cell carcinoma.

It is important to recognize that the diagnoses described herein are based solely on the written terms presented in various reports and tables in the NTP archives. As per NTP procedures, Pathology Working Groups reviewed the accuracy of lesion diagnoses and descriptive nomenclature at the time each study was conducted. However, examination of histology slides was not repeated for the purposes of this data review.

### B. Results (Table 6)

The data in Table 1 show that the correlation of genotoxicity with lung tumor outcome is poor. Two (one equivocal) compounds were genotoxic but failed to induce lung tumors (2-methylimidazole and anthraquinone), three compounds were not genotoxic but did induce lung tumors (oxymetholone, gallium arsenide, vanadium pentoxide), and two compounds were positive for both genotoxicity and lung tumor formation (urethane, riddelliine). It is of value to note that lung tumors were identified in animals given compound by different routes of exposure (Table 6) that include inhalation (gallium arsenide, vanadium pentoxide, indium phosphide), oral gavage (oxymetholone, riddelliine), drinking water (urethane), and diet (o-nitrotoluene), suggesting that direct irritancy that might occur during inhalation is not a prerequisite for initiation of lung tumors, and that other mechanisms of action are also relevant.

As shown in Table 1, seven of the sixteen compounds were identified as inducing lung tumor formation in at least one cell of the two-year bioassay. Four of these seven compounds (urethane with/without 5% ethanol, vanadium pentoxide, indium phosphide, gallium arsenide) also had diagnoses of inflammation and/or hyperplasia at thirteen weeks (Table 6). For animals given urethane (with/without 5% ethanol), inflammation, hyperplasia, and lung tumors were seen only in male and female B6C3F1 mice, but not F344 rats. Riddelliine induced lung tumors only in female B6C3F1 mice without any prior diagnoses of inflammation or hyperplasia at thirteen weeks. Vanadium pentoxide was associated with inflammation, hyperplasia, and lung tumors in male and female B6C3F1 mice and male F344 rats; female F344 rats were without lung tumors. Indium phosphide was associated with inflammation, hyperplasia, proteinosis, fibrosis, foreign body at thirteen weeks, and lung tumors in the two-year studies in male and female B6C3F1 mice and male and female F344 rats. Gallium arsenide was associated with inflammation and hyperplasia in both species in the thirteen-week study, but lung tumors were only identified in female F344 rats in the two-year bioassay.

The presence of inflammation and/or hyperplasia at thirteen weeks without emergence of lung tumors at two years was seen in animals given Elmiron or benzophenone. The lung lesion identified in Elmiron-treated rats was a combination of chronic

TABLE 6.—Lung tumor outcomes from National Toxicology Program (NTP) two-year rodent bioassays, with preneoplastic lung toxicological endpoints from corresponding subchronic (thirteen-week) toxicity studies in the mouse and rat.

Chemical	Female mouse	Male mouse	Female rat	Male rat	Correlation
Anthraquinone (NTP 2005a; diet)	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	Positive <sup>a</sup>
Benzophenone (NTP 2006; diet)	No inflammation No tumors	No inflammation No tumors	Inflammation No hyperplasia No tumors	Inflammation No hyperplasia No tumors	False positive <sup>b</sup>
Decalin (NTP 2005b; inhalation)	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	Positive
Elmiron (NTP 2004a; oral gavage)	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	Inflammation Histiocyte infiltration No hyperplasia No tumors	Inflammation Histiocyte infiltration No hyperplasia No tumors	False positive
Fumonisin B <sub>1</sub> (NTP 2001a; diet)	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	Positive
Gallium arsenide (NTP 2000a; inhalation)	No inflammation Hyperplasia Histiocyte infiltration No tumors	No inflammation Hyperplasia Histiocyte infiltration No tumors	No inflammation Histiocyte infiltration No hyperplasia <b>Tumors</b>	No inflammation No hyperplasia Histiocyte infiltration No tumors	Positive
Indium phosphide (NTP 2001b; inhalation)	Inflammation Hyperplasia <b>Tumors</b>	Inflammation Hyperplasia <b>Tumors</b>	Inflammation Hyperplasia <b>Tumors</b>	Inflammation Hyperplasia <b>Tumors</b>	Positive
Methyleugenol (NTP 2000b; oral gavage)	No inflammation No tumors	No inflammation No tumors	No inflammation No tumors	No inflammation No tumors	Positive
2-Methylimidazole (NTP 2004d; diet)	No inflammation No tumors	No inflammation No tumors	No inflammation No tumors	No inflammation No tumors	Positive
o-Nitrotoluene (NTP 2002a; diet)	No inflammation No hyperplasia	No inflammation No hyperplasia	No inflammation No hyperplasia	No inflammation No hyperplasia <b>Tumors</b>	False negative <sup>c</sup>
Oxymetholone (NTP 1999; oral gavage)	No inflammation No hyperplasia No bioassay	No inflammation No hyperplasia No bioassay	No inflammation No hyperplasia <b>Tumors</b>	No inflammation No hyperplasia No tumors	False negative
Propylene glycol mono-t-butyl ether (NTP 2004b; inhalation)	No inflammation No tumors	No inflammation No tumors	No inflammation No tumors	No inflammation No tumors	Positive
Riddelliine (NTP 2003; oral gavage)	No inflammation No hyperplasia <b>Tumors</b>	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	False negative
Triethanolamine (NTP 2004c; topical)	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	No inflammation No hyperplasia No tumors	Positive
Urethane (NTP 2004e; drinking water)	Inflammation Hyperplasia <b>Tumors</b>	Inflammation Hyperplasia <b>Tumors</b>	Inflammation No bioassay	Inflammation No bioassay	Positive
Vanadium pentoxide (NTP 2002b; inhalation)	Inflammation Hyperplasia <b>Tumors</b>	Inflammation Hyperplasia <b>Tumors</b>	Inflammation Hyperplasia No tumors	Inflammation Hyperplasia <b>Tumors</b>	Positive

<sup>a</sup> A positive correlation indicates that the results of the thirteen-week studies accurately predicted either the presence or absence of tumors in a bioassay in at least one species.

<sup>b</sup> A false positive correlation indicates that the data from the thirteen-week studies predicted that lung tumors should have been generated in the bioassay but were absent in all species tested.

<sup>c</sup> A false negative correlation indicates that the data from the thirteen-week studies would not have predicted the generation of tumors in the bioassays, but lung tumors were present in at least one species.

inflammation and infiltration of alveoli by histiocytes, and has been suggested to be a drug-induced lysosomal storage disorder (Nyska et al. 2002). The lesion identified in benzophenone-treated rats was identified only as chronic active inflammation. These data would be considered false positive

findings for the thirteen-week studies as predictors for lung tumor formation.

False negative findings were identified for oxymetholone, riddelliine, and o-nitrotoluene based on the absence of lung pathology identified from the thirteen-week studies but



positive findings of lung tumors in the two-year bioassays. Of these, riddelliine is considered clearly genotoxic. A review of the incidence data for the bioassay studies for each of these compounds clearly supports the identification of compound-induced lung tumors for each.

Seven of sixteen compounds (Fumonisin B<sub>1</sub>, triethanolamine, propylene glycol mono-t-butyl ether, methyleugenol, 2-methylimidazole, anthraquinone, and decalin) that were given to males and females of both species had no lung pathology at thirteen weeks and no lung tumors at two years. These results were rated as being a positive correlation between the findings of the thirteen-week studies and the lack of lung tumors in the two-year bioassay.

Carcinogenicity studies were only conducted in a single species for oxymetholone or urethane.

### C. Discussion/Conclusions

The presence or absence of inflammation and/or alveolar hyperplasia within the lung following thirteen weeks of exposure appeared to correlate with the presence or absence of lung tumors in eleven of sixteen of the chemicals tested, suggesting an association of events occurring after thirteen weeks of exposure with the ultimate expression of neoplasia. However, there were two false positives in which the identification of inflammation and/or alveolar epithelial hyperplasia did not correctly predict the emergence of tumors in a two-year study. There were two cases of compounds considered nongenotoxic in which lung tumors were identified in a two-year study in the absence of lung pathology in a thirteen-week study in either species tested. It is perhaps not surprising that two of the three compounds administered by inhalation (vanadium pentoxide and indium phosphide) induced the broadest and most consistent degree of pulmonary inflammation and subsequent lung tumors in all species tested. The association of particle burden-induced inflammation in the lung and the occurrence of lung tumors have been well studied (Oberdörster 1995), and the results of the analysis presented are consistent with previous findings.

## VIII. SUMMARY AND CONCLUSIONS

*Genotoxicity:* Four of the sixteen chemicals were considered genotoxic based on NTP data (riddelliine, urethane, 2-methylimidazole, and the anthraquinone preparation). Fumonisin B<sub>1</sub> had some published positive genotoxicity data, and three others were considered equivocal genotoxins (decalin, indium phosphide, and o-nitrotoluene).

*Immunosuppressive Activity:* None of the sixteen chemicals showed evidence of direct immunosuppression at doses relevant to the bioassay. There was no clear evidence of neoplasia in elements of the immune system.

*Liver:* Six of the sixteen chemicals evaluated in the HESI CHIS project showed hepatocellular tumors in rats in the two-year bioassay. Of these six, one parameter alone (liver weight)

correctly predicted five of six tumor outcomes. Grouping any other precursor with liver weight (i.e., hypertrophy, necrosis, vacuolation, degeneration, liver enzyme) resulted in six of six correct predictions. For mouse liver, nine of the sixteen chemicals showed hepatocellular tumors. Of these nine, liver weight correctly predicted six of nine tumor outcomes. Grouping other precursors with liver weight (i.e., hypertrophy and cellular foci) resulted in eight of nine correct predictions.

*Kidney:* Five of the sixteen chemicals showed kidney tumors in the rat two-year bioassay, and none caused kidney tumors in mice. All five chemicals caused detectable renal alterations in rats after thirteen weeks of treatment. The feature that consistently gave a positive signal was the nonspecific finding of an increase in kidney weight, both absolute and relative. The combination of kidney weight and a thorough histologic review of the kidneys after thirteen weeks of treatment detected all of the rodent renal tumorigens in this set of studies.

*Lung:* Seven of the sixteen chemicals produced tumors of the lung in either rats and/or mice. The presence of inflammation and/or alveolar hyperplasia in the lung following thirteen weeks of treatment was observed for four of these sixteen chemicals and for three others, suggesting some degree of a possible correlation between short-term events and the ultimate expression of neoplasia. Two compounds that were not clearly genotoxic produced lung tumors in the absence of any discernible precursor effects in the lung.

### Overall Conclusions

Cellular changes indicative of a tumorigenic endpoint can be identified for most, but not all, of the chemicals producing tumors in two-year studies after thirteen weeks of chemical administration using routine evaluations (see Table 7). Thirteen-week studies utilizing conventional endpoints are currently not adequate to identify all nongenotoxic chemicals that will eventually produce tumors in rats and mice after two years.

Additional endpoints are needed to identify some signals not detected with routine evaluation. Such endpoints might include BrdU labeling and a measure of apoptosis.

Detection of "critical" endpoints, or a critical magnitude of effect, in thirteen-week studies may help distinguish between chemicals that will and will not be tumorigenic after two years (i.e., exclude false positives).

The information obtained in the present study provides a foundation for developing alternative strategies for cancer hazard identification. However, a number of issues were identified that will need to be addressed before such a strategy can be implemented with confidence. A key component of the strategy is the identification of compounds that may be carcinogenic because

TABLE 7.—Predictivity of carcinogenic effects on the basis of key events observed in thirteen-week studies in rodents (rats and mice).

Tissue	Correct prediction	Predictors
Liver–rat	5/6 (wt only) 6/6 combined predictors	Weight, hypertrophy, necrosis, vacuolation/degeneration, liver enzyme
Liver–mouse	6/9 (wt only) 8/9 <sup>a</sup> combined predictors	Weight, hypertrophy, cellular foci
Kidney	5/5	Weight, necrosis/apoptosis, hyperplasia
Lung	4/7 6/7 <sup>b</sup> (nongenotoxins)	Inflammation, hyperplasia
Urinary bladder	0/1	Not applicable

<sup>a</sup> The false negative, indium phosphide, was an equivocal genotoxin on the basis of the results of an *in vivo* micronucleus test.

<sup>b</sup> Riddelliine is genotoxic. o-Nitrotoluene was equivocal in an *in vivo* micronucleus test.

of their ability to damage DNA directly. For this purpose, a series of genotoxicity tests is used, that is, *in vitro* tests of mutagenicity and clastogenicity and an *in vivo* micronucleus test. While it was possible to classify some compounds as clearly genotoxic and clearly nongenotoxic, several were considered equivocal on the basis of the results of such tests. Hence, there is a need for a reliable battery of tests to ensure the identification of compounds that are potentially genotoxic carcinogens (Kirkland et al. 2007). Primarily, the emphasis in defining “genotoxic” carcinogens is often on DNA-reactive compounds, but the broader definition of genotoxicity includes a wide range of genomic damage/disturbance, including potential for aneuploidy induction, which is detectable in the micronucleus assay.

The strategy also relies upon the reliable detection of direct immunosuppressive effects of compounds from conventional endpoints measured in short-term studies (e.g., twenty-eight or ninety days). To the extent that it was possible to test this on the basis of the chemicals studied, the approach appears reliable. However, further work is necessary using a range of known positive and negative compounds.

The endpoints assessed in the thirteen-week studies were based on common key events in the MOAs that have been established for nongenotoxic carcinogens (e.g., organ weight as a surrogate for hyperplasia and inflammation). While many of the compounds that were carcinogenic caused signal effects in thirteen-week studies consistent with a nongenotoxic MOA, there were exceptions, particularly in lung and to a lesser extent in liver. However, a known limitation of the study was that the endpoints studied at thirteen weeks did not encompass all of the known key events for potential MOAs of concern. Hence, there was no direct information available on cell proliferation rate, hyperplasia, or apoptosis. For the proposed strategy to succeed, measures of these endpoints will need to be incorporated into conventional study design, or novel biomarkers of these effects will have to be developed and included in some screening level assessment. This could either be in short-term (perhaps even *in vitro*) or in longer-term (e.g., thirteen-week) studies.

The rapid advances in toxicogenomics hold promise of delivering biomarkers that will enable identification of the key biological pathways affected by chemicals. This should

provide a basis for defining potential MOAs for these compounds (Frijters et al. 2007).

The present study was designed such that it was possible to evaluate the false negative rate of the proposed strategy. The false positive rate was not determined systematically—it would be necessary to evaluate all of the chemicals in the database over the interval 2000 to 2005. However, even with the limited number of chemicals studied here, it was apparent that the false positive rate in the sixteen that were carcinogenic in at least one of the target organs studied was not inconsiderable. Further work is necessary to determine the basis of this. It is possible that more detailed analysis of the magnitude of the response and the dose-response relationship for carcinogens and noncarcinogens would permit such discrimination. In the longer term, incorporation of some of the novel endpoints discussed above should enable much better discrimination between true and false positives.

The two-year bioassay in rats and mice is, at best, only an indicator of potential hazard. Where the MOA for the (nongenotoxic) carcinogenic response is known, it is apparent that the results of the two-year bioassay are frequently falsely positive with respect to risk of human carcinogenicity (Boobis et al. 2006; Cohen 2004; Holsapple et al. 2006; Meek et al. 2003). This suggests that findings in thirteen-week studies would also be falsely positive with respect to their relevance to cancer in humans. The goal of the proposed strategy is the detection of compounds that are potentially carcinogenic to humans. Hence, rather than having to detect all carcinogens in rats and mice by utilizing histopathologic and other biomarkers of key events for MOAs relevant to humans, such as degeneration, apoptosis, and regeneration, combined with knowledge of the pathways leading to these effects, it would be possible to focus effort on those compounds that are of potential concern. This is an issue that requires critical consideration, since the overall intent of these screening assays, whether two-year bioassays or otherwise, is to detect potential human carcinogens.

The association between MOAs and key events needs to be evaluated in terms of human relevance. Such an evaluation needs to include an understanding of exposure levels in terms of both compound kinetics and dynamics in the rodent and human model (Cohen 2004; Holsapple et al. 2006). It is therefore proposed that there should be a prospective approach to

define and understand key carcinogenic events with a well-defined dose-response relationship. This information should then be used to determine human relevance in association with human exposure risk assessment (Cohen et al. 2004). This new approach would mitigate routinely relying on data from the two-year bioassay in rats and mice.

The successful development of a strategy such as that proposed here would enable a more mechanistic, science-based approach to the identification of cancer hazard of chemicals. It would provide a systematic means of implementing the insights provided by consideration of MOA and human relevance. Ultimately, the decisions made would be more reliable yet less resource-consuming.

#### ACKNOWLEDGMENTS

The authors extend their sincere appreciation to the following scientists: Dr. John R. Bucher for providing guidance for searching and extracting data from the National Toxicology Program (NTP) database; Dr. Vijay Reddy for analysis of structural alerts for mutagenic potential and Dr. John Ashby for confirming the results; Drs. Julian Preston, James Klaunig, Mark Cartwright, and Michael Holsapple for peer-reviewing the results of NTP database queries; and Dr. Jay Goodman for his leadership and guidance during the Health and Environmental Sciences Institute (HESI) peer review of this article prior to journal submission.

#### ABOUT HESI

The Health and Environmental Sciences Institute (HESI) is a global branch of the International Life Sciences Institute (ILSI), a public, nonprofit scientific foundation with branches throughout the world. HESI provides an international forum to advance the understanding and application of scientific issues related to human health, toxicology, risk assessment and the environment. HESI is widely recognized among scientists from government, industry and academia as an objective, science-based organization within which important issues of mutual concern can be discussed and resolved in the interest of improving public health. As part of its public benefit mandate, HESI's activities are carried out in the public domain, generating data and other information for broad scientific use and application. Further information about HESI can be found at <http://www.hesiglobal.org>.

#### REFERENCES

- Alden, C. L., Smith, P. F., Piper, C. E., and Brej, L. (1996). A critical appraisal of the value of the mouse cancer bioassay in safety assessment. *Toxicol Pathol* **24**, 722–25.
- Allen, D. G., Pearse, G., Haseman, J. K., and Maronpot, R. R. (2004). Prediction of rodent carcinogenesis: An evaluation of prechronic liver lesions as fore-casters of liver tumors in NTP carcinogenicity studies. *Tox Pathol* **32**, 393–401.
- Ames, B. N. (1973). Carcinogens are mutagens: Their detection and classification. *Environ Health Perspect* **6**, 115–18.
- Ames, B. N., Durston, W. E., Yamasaki, E., and Lee, F. D. (1973). Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. *Proc Natl Acad Sci USA* **70**, 2281–85.
- Ames, B. N., and Gold, L. S. (1997). The causes and prevention of cancer: gaining perspective. *Environ Health Perspect* **105** (Suppl. 4), 865–73.
- Aranda, M., Perez-Alzola, L. P., Ellahuene, M. F., and Sepulveda, C. (2000). Assessment of in vitro mutagenicity in Salmonella and in vivo genotoxicity in mice of the mycotoxin fumonisin B1. *Mutagenesis* **15**, 469–71.
- Armitage, P., and Doll, R. (1954). The age distribution of cancer and a multi-stage theory of carcinogenesis. *Int J Epidemiol* **33**, 1174–79.
- Ashby, J., and Purchase, I. F. H. (1993). Will all chemicals be carcinogenic to rodents when adequately evaluated? *Mutagenesis* **8**, 489–93.
- Bean, C. L., Armstrong, M. J., and Galloway, S. M. (1992). Effect of sampling time on chromosome aberration yield for 7 chemicals in Chinese hamster ovary cells. *Mutat Res* **265**, 31–44.
- Berenblum, I., ed. (1969). Carcinogenicity testing. A Report of the Panel on Carcinogenicity of the Cancer Research Commission of UICC, vol 2. Geneva, Switzerland: International Union Against Cancer.
- Berenblum, I., and Shubik, P. (1947). A quantitative approach to the study of the stages of chemical carcinogenesis in the mouse skin. *Br J Cancer Res* **1**, 383–91.
- Berenblum, I., and Shubik, P. (1949). The persistence of latent tumour cells induced in the mouse's skin by a single application of 9,10-dimethyl-1,2-benzanthracene. *Br J Cancer Res* **3**, 384–86.
- Boobis, A. R., Cohen, S. M., Dellarco, V., McGregor, D., Meek, M. E., Vickers, C., Willcocks, D., and Farland, W. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. *Crit Rev Toxicol* **36**, 781–92.
- Bucci, T. J., Howard, P. C., Tolleson, W. H., Laborde, J. B., and Hansen, D. K. (1998). Renal effects of fumonisin mycotoxins in animals. *Toxicol Pathol* **26**, 160–64.
- Butterworth, B. E., and Bogdanffy, M. S. (1999). A comprehensive approach to the integration of toxicity and cancer risk assessment. *Regul Toxicol Pharmacol* **29**, 23–36.
- Butterworth, B. E., Mathre, O. B., and Ballinger, K. (2001). The preparation of anthraquinone used in the National Toxicology Program cancer bioassay was contaminated with the mutagen 9-aminoanthracene. *Mutagenesis* **16**, 169–77.
- Cohen, S. M. (1998a). Cell proliferation and carcinogenesis. *Drug Metab Rev* **30**, 339–57.
- Cohen, S. M. (1998b). Cell proliferation in the evaluation of carcinogenic risk and the inadequacies of the initiation-promotion model. *Int J Toxicol* **17**, 129–42.
- Cohen, S. M. (2004). Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. *Toxicol Sci* **80**, 225–29.
- Cohen, S. M., and Ellwein, L. B. (1990). Cell proliferation in carcinogenesis. *Science* **249**, 1007–11.
- Cohen, S. M., and Ellwein, L. B. (1991). Genetic errors, cell proliferation, and carcinogenesis. *Cancer Res* **51**, 6493–505.
- Cohen, S. M., Klaunig, J., Meek, M. E., Hill, R. N., Pastoor, T., Lehman-McKeeman, L., Bucher, J., Longfellow, D. G., Seed, J., Dellarco, V., and Fenner-Crisp, P. (2004). Evaluating the human relevance of chemically-induced animal tumors. *Toxicol Sci* **78**, 181–86.
- Doi, A. M., Irwin, R. D., and Bucher, J. R. (2005). Influence of functional group substitutions on the carcinogenicity of anthraquinone in rats and mice: Analysis of long-term bioassays by the National Cancer Institute and the National Toxicology Program. *J Toxicol Environ Health B Crit Rev* **8**, 109–26.
- Dragan, Y. P., Bidlack, W. R., Cohen, S. M., Goldsworth, T. L., Hard, G. C., Howard, P. C., Riley, R. T., and Voss, K. A. (2001). Implication of apoptosis for toxicity, carcinogenicity, and risk assessment: Fumonisin B<sub>1</sub> as an example. *Toxicol Sci* **61**, 6–17.
- Druckrey, H. (1967). Quantitative aspects in chemical carcinogenesis. In *Potential carcinogenic hazards from drugs*, UICC Monograph Series vol. 7, ed. ed. R. Truhaut, 60–78. New York: Springer-Verlag.
- Dybing, E., and Sanner, T. (1999). Species differences in chemical carcinogenesis of the thyroid gland, kidney and urinary bladder. In *Species*

- differences in thyroid, kidney and urinary bladder carcinogenesis, no. 147, ed. C. C. Capen, E. Dybing, J. M. Rice, and J. D. Wilbourn, 15–32. Lyon, France: IARC Scientific Publications.
- Elcombe, C. R., Odum, J., Foster, J. R., Stone, S., Hasmlal, S., Soames, A. R., Kimber, I., and Ashby, J. (2002). Prediction of rodent nongenotoxic carcinogenesis: Evaluation of biochemical and tissue changes in rodents following exposure to 9 nongenotoxic NTP carcinogens. *Environ Health Perspect* **110**, 363–75.
- Ennever, F. K., and Lave, L. B. (2003). Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. *Regul Toxicol Pharmacol* **38**, 52–57.
- Epstein, S. S. (1979). *The politics of cancer*. New York: Anchor.
- Foulds, L. (1954). The experimental study of tumor progression: A review. *Cancer Res* **14**, 327–39.
- Frijters, R., Verhoeven, S., Alkema, W., van Schaik, R., and Polman, J. (2007). Literature-based compound profiling: Application to toxicogenomics. *Pharmacogenomics* **8**, 1521–34.
- Fung, V. A., Barrett, J. C., and Huff, J. E. (1995). The carcinogenesis bioassay in perspective: application in identifying human cancer hazard. *Environ Health Perspect* **103**, 680–83.
- Galloway, S. M., Aardema, M. J., Ishidate, M., Ivett, J. L., Kirkland, D. J., Morita, T., Mosesso, P., and Sofuni, T. (1994). Report from the working group on in vitro tests for chromosomal aberrations. *Mutat Res* **312**, 241–61.
- Gaylor, D. W. (2005). Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? *Regul Toxicol Pharmacol* **41**, 128–33.
- Goodman, J. I., and Watson, R. E. (2002). Altered DNA methylation: A secondary mechanism involved in carcinogenesis. *Annu Rev Pharmacol Toxicol* **42**, 501–25.
- Greenfield, R. E., Ellwein, L. B., and Cohen, S. M. (1984). A general probabilistic model of carcinogenesis: Analysis of experimental urinary bladder cancer. *Carcinogenesis* **5**, 437–45.
- Grulich, A. E., Van Leeuwen, M. T., Falster, M. O., and Vajdic, C. M. (2007). Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. *Lancet* **370**, 59–67.
- Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. *Cell* **100**, 57–70.
- Hard, G. C., Howard, P. C., Kovatch, R. M., and Bucci, T. J. (2001). Rat kidney pathology induced by chronic exposure to Fumonisin B1 includes rare variants of renal tubule tumor. *Environ Pathol* **29**, 379–86.
- Hard, G. C., Johnson, K. J., and Cohen, S. M. (2009). A comparison of rat chronic progressive nephropathy (CPN) with human renal disease—Implications for human risk assessment. *Crit Rev Toxicol* **39**, 332–46.
- Haseman, J. K. (1984). Statistical issues in the design, analysis, and interpretation of animal carcinogenicity studies. *Environ Health Perspect* **58**, 385–92.
- Holsapple, M. P., Pitot, H. C., Cohen, S. M., Boobis, A. R., Klaunig, J. E., Pastoor, T., Dellarco, V. L., and Dragan, Y. P. (2006). Mode of action in relevance of rodent liver tumors to human cancer risk. *Toxicol Sci* **89**, 51–56.
- Hoshi, M., Morimura, K., Wanibuchi, H., Wei, M., Okochi, E., Ushijima, T., Takaoka, K., and Fukushima, S. (2004). No-observed effect levels for carcinogenicity and for in vivo mutagenicity of a genotoxic carcinogen. *Toxicol Sci* **81**, 273–79.
- Howard, P., Warbritton, A., Voss, K., Lorentzen, R., Thurman, D., Kovach, R., and Bucci, T. (2001). Compensatory regeneration as a mechanism for renal tubule carcinogenesis of fumonisin B1 in the F344/N/NCTR BR rat. *Environ Health Perspect Suppl* **109** (Suppl. 2), 309–14.
- International Conference on Harmonisation. (2005). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonized Tripartite Guideline. Immunotoxicity Studies for Human Pharmaceuticals. S8. <http://www.ich.org/LOB/media/MEDIA1706.pdf>
- Kirkland, D. J., Aardema, M., Banduhn, N., Carmichael, P., Fautz, R., Meunier, J. R., and Pfuhrer, S. (2007). In vitro approaches to develop weight of evidence (WoE) and mode of action (MoA) discussions with positive in vitro genotoxicity results. *Mutagenesis* **22**, 61–75.
- Kirkland, D., Aardema, M., Henderson, L., and Müller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. I. Sensitivity, specificity and relative predictivity. *Mutat Res* **584**, 1–256. (Erratum in *Mutat Res* **588**, 70).
- Klein, G., and Klein, E. (1984). Commentary: Oncogene activation and tumor suppression. *Carcinogenesis* **5**, 3362–64.
- Knudson, A. G. (1971). Mutation and cancer: Statistical study of retinoblastomas. *Proc Natl Acad Sci* **68**, 820–23.
- Lerda, D., Biaggi-Bistoni, M., Peralta, N., Ychari, S., Vazquez, M., and Bosio, G. (2005). Fumonisin in foods from Cordoba (Argentina): Presence and genotoxicity. *Food Chem Toxicol* **43**, 691–98.
- Lock, E. A., and Hard, G. C. (2004). Chemically induced renal tubule tumors in the laboratory rat and mouse: Review of the NCI/NTP database and categorization of renal carcinogens on mechanistic information. *Crit Rev Toxicol* **34**, 211–99.
- MacDonald, J., French, J. E., Gerson, R. J., Goodman, J., Inoue, T., Jacobs, A., Kasper, P., Keller, D., Lavin, A., Long, G., McCullough, B., Sistare, F. D., Storer, R., and van der Laan, J. W., ILSI HESI Alternative to Carcinogenicity Testing Committee. (2004). The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward. *Toxicol Sci* **77**, 188–94.
- MacDonald, J. S., and Scribner, H. E. (1999). The maximum tolerated dose and secondary mechanisms of carcinogenesis. In *Carcinogenicity*, ed. K. T. Kitchin, chap. 3, 125–44. New York: Marcel-Dekker.
- Matthews, E. J., Kruhlak, N. L., Cimino, M. C., Benz, R. D., and Contrera, J. F. (2006). An analysis of genetic toxicity, reproductive and developmental toxicity and carcinogenicity data. II. Identification of genotoxicants, reprotoxicants and carcinogens using in silico methods. *Regul Toxicol Pharmacol* **44**, 97–110.
- Meek, M. E., Bucher, J. R., Cohen, S. M., Dellarco, V., Hill, R. N., Lehman-McKeeman, L. D., Longfellow, D. G., Pastoor, T., Seed, J., and Patton, D. E. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. *Crit Rev Toxicol* **33**, 591–653.
- Moolgavkar, S. H., and Knudson, A. G., Jr. (1981). Mutation and cancer: A model for human carcinogenesis. *J Natl Cancer Inst* **66**, 1037–45.
- National Toxicology Program. (1999). Toxicology and carcinogenesis studies of Oxymetholone (CAS No. 434-07-1) in F344 rats and toxicology studies of oxymetholone in B6C3F1 mice (Gavage Studies). NTP Technical Report Series 485, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr485.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr485.pdf)
- National Toxicology Program. (2000a). Toxicology and carcinogenesis studies of Gallium Arsenide (CAS No. 1303-00-0) in F344/N rats and B6C3F1 mice (Inhalation Studies). NTP Technical Report Series 492, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr492.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr492.pdf)
- National Toxicology Program. (2000b). Toxicology and carcinogenesis studies of Methyleugenol (CAS NO. 93-15-2) in F344/N rats and B6C3F1 mice (Gavage Studies). NTP Technical Report Series 491, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr491.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr491.pdf)
- National Toxicology Program. (2001a). Toxicology and carcinogenesis studies of Fumonisin B1 (CAS No. 116355-83-0) in F344/N rats and B6C3F1 mice (Feed Studies). NTP Technical Report Series 496, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr496.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr496.pdf)
- National Toxicology Program. (2001b). Toxicology and carcinogenesis studies of Indium Phosphide (CAS No. 22398-80-7) in F344/N rats and B6C3F1 mice (Inhalation Studies). NTP Technical Report Series 499, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr499.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr499.pdf)
- National Toxicology Program. (2002a). Toxicology and carcinogenesis studies of o-Nitrotoluene (CAS No. 88-72-2) in F344/N rats and B6C3F1 mice (Feed Studies). NTP Technical Report Series 504, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr504.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr504.pdf)
- National Toxicology Program. (2002b). Toxicology and carcinogenesis studies of Vanadium Pentoxide (CAS No. 1314-62-1) in F344/N rats and B6C3F1 mice (Inhalation). NTP Technical Report Series 507, NIEHS,

- Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr507.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr507.pdf)
- National Toxicology Program. (2003). Toxicology and carcinogenesis studies of Riddelliine (CAS No. 23246-96-0) in F344/N rats and B6C3F<sub>1</sub> mice (Gavage Studies). NTP Technical Report Series 508, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr508.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr508.pdf)
- National Toxicology Program. (2004a). Toxicology and carcinogenesis studies of Elmiron<sup>®</sup> (CAS No. 37319-17-8) in F344/N rats and B6C3F<sub>1</sub> mice (Gavage Studies). NTP Technical Report Series 512, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr512.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr512.pdf)
- National Toxicology Program. (2004b). Toxicology and carcinogenesis studies of Propylene Glycol Mono-t-Butyl Ether (CAS No. 57018-52-7) in F344/N rats and B6C3F<sub>1</sub> mice and a toxicology study of Propylene Glycol Mono-t-Butyl Ether in male NBR rats (Inhalation Studies). NTP Technical Report Series 515, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr515.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr515.pdf)
- National Toxicology Program (2004c). Toxicology and carcinogenesis studies of Triethanolamine (CAS No. 102-71-6) in B6C3F<sub>1</sub> mice (Dermal Studies). NTP Technical Report Series 518, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/ntp/htdocs/LT\\_rpts/tr518.pdf](http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr518.pdf)
- National Toxicology Program. (2004d). Toxicology and carcinogenesis studies of 2-Methylimidazole (CAS No. 693-98-1) in F344/N rats and B6C3F<sub>1</sub> mice (Feed Studies). NTP Technical Report Series 516, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/files/516final\\_web.pdf](http://ntp.niehs.nih.gov/files/516final_web.pdf)
- National Toxicology Program (2004e). Toxicology and carcinogenesis studies of Urethane, Ethanol, and Urethane/Ethanol (Urethane, CAS No. 51-79-6; Ethanol, CAS No. 64-17-5) in B6C3F<sub>1</sub> mice (Drinking Water Studies). NTP Technical Report Series 510, NIEHS, Research Triangle Park, NC. <http://ntp.niehs.nih.gov/files/tr510-full.pdf>
- National Toxicology Program. (2005a). Toxicology and carcinogenesis studies of Anthraquinone (CAS No. 84-65-1) in F344/N rats and B6C3F<sub>1</sub> mice (Feed Studies). NTP Technical Report Series 494, NIEHS, Research Triangle Park, NC. <http://ntp.niehs.nih.gov/files/TR494web1.pdf>
- National Toxicology Program. (2005b). Toxicology and carcinogenesis studies of Decalin (CAS No. 91-17-8) in F344/N rats and B6C3F<sub>1</sub> mice and a toxicology study of Decalin in male NBR rats (Inhalation Studies). NTP Technical Report Series 513, NIEHS, Research Triangle Park, NC. <http://ntp.niehs.nih.gov/files/TR-513.pdf>
- National Toxicology Program. (2006). Toxicology and carcinogenesis studies of Benzophenone (CAS No. 119-61-9) in F344/N rats and B6C3F<sub>1</sub> mice (Feed Studies). NTP Technical Report Series 533, NIEHS, Research Triangle Park, NC. [http://ntp.niehs.nih.gov/files/533\\_Web.pdf](http://ntp.niehs.nih.gov/files/533_Web.pdf)
- Norred, W. P., Plattner, R. D., Vesonder, R. F., Bacon, C. W., and Voss, K. A. (1992). Effects of selected secondary metabolites on Fusarium moniliforme on unscheduled synthesis of DNA by rat primary hepatocytes. *Food Chem Toxicol* **30**, 233–37.
- Norton, N., ed. (1981). *Assessment of technologies for determining cancer risks from the environment*. Washington, DC: Office of Technology Assessment.
- Nyska, A., Nold, J. B., Johnson, J. D., and Abdo, K. (2002). Lysosomal-storage disorder induced by Elmiron following 90-days gavage administration in rats and mice. *Toxicol Pathol* **30**, 178–87.
- Oberdörster, G. (1995). Lung particle overload: Implications for occupational exposures to particles. *Regul Toxicol Pharmacol* **21**, 123–35.
- Rhomberg, L. R., Baetcke, K., Blancato, J., Bus, J., Cohen, S., Conolly, R., Dixit, R., Doe, J., Ekelman, K., Fenner-Crisp, P., Harvey, P., Hattis, D., Jacobs, A., Jacobson-Kram, D., Lewandowski, T., Liteplo, R., Pelkonen, O., Rice, J., Somers, D., Turturro, A., West, W., and Olin, S. (2007). Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: Approaches to dose selection. *Crit Rev Toxicol* **37**, 729–837.
- Roe, F. J. (1989). What is wrong with the way we test chemicals for carcinogenic activity? In *Advances in applied toxicology*, ed. A. D. Dayan and A. J. Paine, chap. 2, 2–17. London: Taylor & Francis.
- Serraino, D., Piselli, P., Busnach, G., Burra, P., Citterio, F., Arbustini, E., Bacarani, U., De Juli, E., Pozzetto, U., Bellelli, S., Polesel, J., Pradier, C., Dal Maso, L., Angeletti, C., Carrieri, M. P., Rezza, G., and Franceschi, S. (2007). Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. *Eur J Cancer* **43**, 2117–23.
- Sonich-Mullin, C., Fielder, R., Wiltse, J., Baetcke, K., Dempsey, J., Fenner-Crisp, P., Grant, D., Hartley, M., Knaap, A., Kroese, D., Mangelsdorf, I., Meek, E., Rice, J. M., and Younes, M., International Programme on Chemical Safety. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. *Regul Toxicol Pharmacol* **34**, 146–52.
- Swenberg, J. A., Ham, A., Koc, H., Morinello, E., Ranasinghe, A., Tretyakova, N., Upton, P. B., and Wu, K. (2002). DNA adducts: Effects of low exposure to ethylene oxide, vinyl chloride and butadiene. *Mutat Res* **464**, 77–86.
- Tweats, D. J., Blakey, D., Heflich, R. H., Jacobs, A., Jacobsen, S. D., Morita, T., Nohmi, T., O'Donovan, M. R., Sasaki, Y. F., Sofuni, T., and Tice, R., IWGT Working Group. (2007). Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests. I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards. *Mutat Res* **627**, 78–91.
- U.S. Environmental Protection Agency. (2002). Hepatocellular hypertrophy, HED Guidance Document #G2002.01. Washington, DC: US EPA HED Toxicology Science Advisory Council.
- U.S. Environmental Protection Agency. (2005). Guidelines for carcinogen risk assessment, EPA/630/P-03/001F. Washington, DC: National Center for Environmental Assessment.
- U.S. Food and Drug Administration. (1996). Guideline for industry. Specific aspects of regulatory genotoxicity tests for pharmaceuticals. ICH S2A. <http://www.fda.gov/cder/guidance/ichs2a.pdf>
- Van Oosterhout, J. P., van der Laan, J. W., De Waal, E. J., Olejniczak, K., Hilgenfeld, M., Schmidt, V., and Bass, R. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. *Regul Toxicol Pharmacol* **25**, 6–17.
- Voss, K. A., Chamberlain, W. J., Bacon, C. W., Herbert, R. A., Walters, D. B., and Norred, W. P. (1995). Subchronic feeding study of the mycotoxin fumonisin B1 in B6C3F<sub>1</sub> mice and Fischer 344 rats. *Fund Appl Toxicol* **24**, 102–10.
- Weisburger, E. K. (1981). Techniques for carcinogenicity studies. *Cancer Res* **41**, 3690–94.
- Weisburger, E. K. (1983). History of the bioassay program of the National Cancer Institute. *Prog Exp Tumor Res* **26**, 187–201.
- Weisburger, J. H., and Williams, G. M. (1981). Carcinogen testing: Current problems and new approaches. *Science* **214**, 401–7.
- Williams, G. M., Iatropoulos, M. J., and Jeffrey, A. M. (2004). Thresholds for the effects of 2-acetylaminofluorene in rat liver. *Toxicol Pathol* **32**, 85–91.

For reprints and permissions queries, please visit SAGE's Web site at <http://www.sagepub.com/journalsPermissions.nav>

## RFR Attachment 2

EPA's September 21, 2018 response to RFC #18001



UNITED STATES ENVIRONMENTAL PROTECTION  
AGENCY WASHINGTON, D.C. 20460

OFFICE OF  
RESEARCH AND DEVELOPMENT

September 21, 2018

Jerry Cook  
Technical Director  
Chemical Products Corporation  
102 Old Mill Road  
Post Office Box 2470  
Cartersville, Georgia 30120

Dear Mr. Cook:

This letter is in response to the Request for Correction (RFC) received by the U.S. Environmental Protection Agency (EPA) on April 6, 2018, which was assigned RFC #18001 for tracking purposes. In the RFC letter, Chemical Products Corporation (CPC) states that *Provisional Peer Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)*, disseminated by EPA's Office of Research and Development (ORD) in 2011 (referred to herein as the "9,10-AQ PPRTV"), and the toxicity values for 9,10-anthraquinone (9,10-AQ) provided in EPA's Regional Screening Level (RSL) Tables, disseminated by EPA's Office of Land and Emergency Management (OLEM), do not reflect "sound and objective scientific practices" as required by EPA's *Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility and Integrity of Information Disseminated by the Environmental Protection Agency* (IQGs) and requests correction.

### Summary of the Request

The CPC RFC requests the 9,10-AQ PPRTV be withdrawn and revised and that the toxicity values for 9,10-AQ be removed from the RSL Tables pending revision of the 9,10-AQ PPRTV. To support this RFC, CPC provided a letter detailing purported deficiencies in a 2-year bioassay of 9,10-AQ conducted by the National Toxicology Program (NTP) (this NTP bioassay is referred to herein as "TR 494"). The CPC RFC asserts that TR 494 does not represent "sound and objective scientific practices" as required by EPA's IQGs. Specifically, the RFC further asserts that the 9,10-AQ PPRTV and the 9,10-AQ toxicity values provided in the RSL Tables do not comply with EPA's IQGs due to the use of information from TR 494 in their development.

### Background

NTP routinely develops and disseminates scientific information about hazardous and potentially toxic chemicals. Bioassays conducted by NTP are conducted in compliance with Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations and undergo quality assurance audits, public comment and external peer review. TR 494 includes the results of toxicity testing conducted by NTP in male and female F344/N rats and B6C3F1 mice exposed to 9,10-AQ in the diet for 14 weeks or 2 years. TR 494 also contains the results of genetic toxicology testing conducted in *Salmonella typhimurium*, mouse bone marrow cells, and mouse peripheral blood erythrocytes.

In developing the 9,10-AQ PPRTV, EPA carefully evaluated all available toxicity information for 9,10-AQ. As part of this evaluation, TR 494 was determined to be an appropriate study for use in developing toxicity values and was utilized for the derivation of screening subchronic and chronic non-cancer oral Reference Doses (RfDs) and an oral slope factor (OSF) for 9,10-AQ. The 9,10-AQ PPRTV was developed following all applicable EPA guidelines and was externally peer reviewed by independent scientific experts.

Following completion of the 9,10-AQ PPRTV, the 9,10-AQ toxicity values derived in the PPRTV were included in the RSL Tables.

### **The EPA Response to CPC Request for Correction**

In the Attachments to this response, EPA addresses the assertions raised in the RFC that are relevant to the science evaluation and information presented in the 9,10-AQ PPRTV and the RSL Tables under EPA's IQGs.

In Attachment 1, EPA addresses the following issues as detailed in the CPC RFC:

A. TR 494 presents conclusions which are not scientifically sound and do not comply with EPA's IQGs

1. Mutagenicity testing of Sample A07496
2. Storage of TR 494 test article

B. There is no scientifically sound basis for concluding that non-mutagenic 9,10-AQ caused cancers in NTP TR 494

C. There is no scientifically sound basis for considering non-mutagenic 9,10-AQ likely to be carcinogenic to humans

D. EPA's screening levels for 9,10-AQ do not reflect sound and objective scientific practices

1. The 9,10-AQ PPRTV should be withdrawn
2. 9,10-AQ should be removed from the RSL Tables

In Attachment 2, EPA provides the results of a study quality evaluation of TR 494 conducted in response to this RFC.

### **Conclusion**

After carefully reviewing the RFC submitted by CPC and conducting a study quality evaluation of TR 494, EPA has concluded that the underlying information and conclusions presented in *Provisional Peer Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)* and the toxicity values for 9,10-AQ found in the Regional Screening Level Tables are consistent with EPA's IQGs.


Additionally, each of the purported deficiencies in TR 494 detailed in the CPC RFC has been specifically addressed by the National Institute of Environmental Health Sciences (NIEHS) in response to Requests for Correction and Requests for Reconsideration previously submitted by CPC to NIEHS. No new relevant information regarding TR 494 was provided in this RFC. NIEHS has concluded that there is no evidence of noncompliance with National Institutes of Health (NIH) and Health and Human Services (HHS) Information Quality Guidelines for TR 494.



## Your Right to Appeal

If you are dissatisfied with the response, you may submit a Request for Reconsideration (RFR) as described in EPA's Information Quality Guidelines. The EPA requests that any such RFR be submitted within 90 days of the date of the EPA's response. If you choose to submit an RFR, please send a written request to the EPA Information Quality Guidelines Processing Staff via mail (Information Quality Guidelines Processing Staff, Mail Code 282IT, USEPA, 1200 Pennsylvania Avenue, NW, Washington, DC 20460); or electronic mail ([quality@epa.gov](mailto:quality@epa.gov)). If you submit a RFR, please reference the case number assigned to this original Request for Correction (RFC #18001). Additional information about how to submit an RFR is listed on the EPA Information Quality Guidelines website at <http://epa.gov/quality/informationguidelines/index.html>.

Sincerely,



Jennifer Orme-Zavaleta, Ph.D.  
Principal Deputy Assistant Administrator for Science  
Office of Research and Development

Cc: Vaughn Noga, OEI  
Vincia Holloman, OEI  
Kevin Kirby, OEI  
Tina Bahadori, NCEA  
Mary Ross, NCEA  
Annette Gatchett, NCEA  
Belinda Hawkins, NCEA  
Kevin DeBell, AO

Attachment 1: U.S. EPA Response to the Chemical Products Corporation (CPC) Request for Correction (RFC) of *Provisional Peer Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)* and the Regional Screening Levels for 9,10-Anthraquinone

Attachment 2: Study Quality Evaluation of *NTP Technical Report on the Toxicology and Carcinogenesis Studies of Anthraquinone (CAS No. 84-65-1) in R344/N Rats and B6C3F1 Mice (Feed Studies)* ("TR 494")

**Attachment 1**

**U.S. EPA Response to the Chemical Products Corporation (CPC) Request for Correction (RFC) of  
*Provisional Peer Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)* and the Regional  
Screening Levels for 9,10-Anthraquinone**

**September 2018**

National Center for Environmental Assessment  
Office of Research and Development  
U.S. Environmental Protection Agency

## The Request

The Chemical Products Corporation (CPC) Request for Correction (RFC) requests the 9,10-anthraquinone (9,10-AQ) Provisional Peer Reviewed Toxicity Value (PPRTV) assessment “be immediately withdrawn and revised to provide toxicity values ... based upon sound science” and that 9,10-AQ “be immediately removed from EPA’s Regional Screening Level Tables” pending revision of the 9,10-AQ PPRTV.

To support the RFC, CPC asserts that EPA “should not consider the conclusions presented in National Toxicology Program Technical Report 494 (TR-494) to represent valid peer-reviewed toxicity values or sound science because peer reviewers were presented false information by NTP staff which prevented the Peer Review Panel from rendering a sound scientific judgement.”

## Response

In this response, EPA is addressing the assertions raised in the RFC that may be relevant to the derivation and dissemination of EPA toxicity values under EPA’s *Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility and Integrity of Information Disseminated by the Environmental Protection Agency (IQGs)*.

Specifically, EPA is addressing the following topics as raised in the CPC RFC:

- A. TR 494 presents conclusions which are not scientifically sound and do not comply with EPA’s IQGs
  - 1. Mutagenicity testing of Sample A07496
  - 2. Storage of TR 494 test article
- B. There is no scientifically sound basis for concluding that non-mutagenic 9,10-AQ caused cancers in NTP TR 494
- C. There is no scientifically sound basis for considering non-mutagenic 9,10-AQ likely to be carcinogenic to humans
- D. EPA’s screening levels for 9,10-AQ do not reflect sound and objective scientific practices
  - 1. The 9,10-AQ PPRTV should be withdrawn
  - 2. 9,10-AQ should be removed from the RSL Tables

In considering this RFC, EPA reviewed the following:

USEPA (2002). “Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity of Information Disseminated by the Environmental Protection Agency” (<https://www.epa.gov/quality/epa-information-quality-guidelines>)

USEPA (2011). “Provisional Peer Reviewed Toxicity Values for 9, 10-Anthraquinone (CASRN 84-65-1)” ([https://hhpprtv.ornl.gov/issue\\_papers/Anthraquinone910.pdf](https://hhpprtv.ornl.gov/issue_papers/Anthraquinone910.pdf))

NTP (2005). “NTP Technical Report on the Toxicology and Carcinogenesis Studies of Anthraquinone (CAS No. 84-65-1) in F344/N Rats and B6C3F1 Mice (Feed Studies)” [TR 494]  
([https://ntp.niehs.nih.gov/ntp/htdocs/lt\\_rpts/tr494.pdf](https://ntp.niehs.nih.gov/ntp/htdocs/lt_rpts/tr494.pdf))

HHS (2002). “Guidelines for Ensuring and Maximizing the Quality, Objectivity, Utility, and Integrity of Information Disseminated to the Public” (<https://aspe.hhs.gov/report/hhs-guidelines-ensuring-and-maximizing-quality-objectivity-utility-and-integrity-information-disseminated-public>)

USEPA (2005). “Guidelines for Carcinogen Risk Assessment” (<https://www.epa.gov/risk/guidelines-carcinogen-risk-assessment>)

May 21, 1999 NTP Board of Scientific Counselors Summary Minutes from Peer Review of Draft Technical Reports of Long-Term Toxicology and Carcinogenesis Studies by the Technical Reports Review Subcommittee  
([https://ntp.niehs.nih.gov/ntp/about\\_ntp/bsc/trrs/1999/may/trrs21may1999mins\\_508.pdf](https://ntp.niehs.nih.gov/ntp/about_ntp/bsc/trrs/1999/may/trrs21may1999mins_508.pdf))

February 17-18, 2004 NTP Board of Scientific Counselors Technical Reports Review Subcommittee Meeting Summary Minutes.  
([https://ntp.niehs.nih.gov/ntp/about\\_ntp/bsc/trrs/2004/feb/trrs17feb2004mins\\_508.pdf](https://ntp.niehs.nih.gov/ntp/about_ntp/bsc/trrs/2004/feb/trrs17feb2004mins_508.pdf))

December 9, 2004 NTP Board of Scientific Counselors Technical Reports Review Subcommittee Meeting Summary Minutes  
([https://ntp.niehs.nih.gov/ntp/about\\_ntp/bsc/trrs/2004/dec/trrs9dec2004mins\\_508.pdf](https://ntp.niehs.nih.gov/ntp/about_ntp/bsc/trrs/2004/dec/trrs9dec2004mins_508.pdf))

Your November 17, 2002 Request for Correction to HHS concerning TR 494  
(<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

The March 19, 2003 HHS response to your Request for Correction (<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

Your March 28, 2003 Request for Reconsideration to HHS (<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

The September 8, 2003 HHS response to your Request for Reconsideration  
(<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

Your February 24, 2004 Request for Correction to HHS concerning TR 494  
(<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

Your March 14, 2005 Request for Correction of Information to HHS concerning TR 494  
(<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

Your May 31, 2006 Request for Correction to HHS concerning TR 494 and the July 13 and July 17, 2006 Addenda (<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

The December 22, 2006 HHS response to your Request for Correction  
(<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

Your January 5, 2007 Request for Reconsideration and the March 1, 2007 Addenda  
(<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

The September 22, 2008 HHS response to your Request for Reconsideration (<https://aspe.hhs.gov/information-requests-corrections-and-hhs-responses>)

Boobis, AR et al. (2009). A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards. *Toxicologic Pathology*, 37: 714-732.

Butterworth, BE et al. (2004). Contamination Is a Frequent Confounding Factor in Toxicology Studies with Anthraquinone and Related Compounds. *International Journal of Toxicology*, 23: 335-344.

Doi, AM et al. (2005). Influence of Functional Group Substitutions on the Carcinogenicity of Anthraquinone in Rats and Mice: Analysis of Long-Term Bioassays by the National Cancer Institute and the National Toxicology Program, *Journal of Toxicology and Environmental Health, Part B*, 8:2, 109-126.

A. TR 494 presents conclusions which are not scientifically sound and do not comply with EPA's IQGs

The CPC RFC asserts that the National Toxicology Program (NTP) Technical Report (TR 494) does not represent "sound science" and that "peer reviewers were presented false information by NTP staff which prevented the Peer Review Panel from rendering a sound scientific judgement." The RFC contends that NTP staff presented false information to a peer review panel "in order to achieve acceptance of the conclusions presented" in TR 494.

More specifically, the RFC asserts that NTP provided peer reviewers with false mutagenicity testing results of the TR 494 test article and false information regarding storage of the TR 494 test article. These issues are addressed separately below.

1. Mutagenicity testing of Sample A07496

The CPC RFC asserts that: "Someone at NTP arranged for the shipment of "Sample A07496" to BioReliance Testing Laboratories and authorized mutagenicity testing of a sample labeled "Sample A07496" by BioReliance with full knowledge that this AQ sample was not the TR-494 test article." The RFC includes two attachments (Attachments 2 & 3) to support this assertion. It also asserts that "peer reviewers were under the false impression that the TR-494 AQ test article had been determined to be non-mutagenic when they approved the conclusions in TR-494."

HHS specifically addressed the issues raised in the current CPC RFC related to the 9,10-AQ samples tested by BioReliance Corp. in their December 22, 2006 response to your May 31, 2006 Request for Correction (as amended on July 13 and July 17) and in their September 22, 2008 Response to your January 5, 2007 Request for Reconsideration (as amended on March 1, 2007). Attachments 2 & 3 in the current RFC were also submitted as attachments to HHS in your January 5, 2007 HHS Request for Reconsideration (as amended on March 1, 2007) and were addressed by HHS in their responses (detailed below).

In their 2006 response, HHS indicated that: "The Methods and Materials section for TR494 identifies the source of the anthraquinone used in the NTP 2-year studies as lot no. 5893. The NTP conducted follow-up genetic toxicology studies on a sample from lot no. 5893 as well as samples of anthraquinone produced by other processes. Appendix E, which contains the results from these follow-up studies, identifies the source of each sample noting that Sample A07496 is from lot no. 5893. Also, in response to Freedom of Information Act requests by CPC filed on March 28, 2006 and July 19, 2006, the NTP sent

you records documenting shipment of lot no. 5893 to BioReliance Corporation for genetic toxicology testing and verifying Sample A07496 as an aliquot from lot no. 5893 (Enclosures 1 and 2, respectively)."

In their 2008 response, HHS indicated that: "... we reviewed the records related to handling of samples in this matter. Those records indicated that Battelle, the analytical chemistry laboratory, shipped 2 g of 4 different lots of anthraquinone to BioReliance, the study laboratory, on June 1, 2004 ... The samples were labeled by lot number, the standard information that is included on samples. BioReliance received the materials on June 2, 2004. You were sent this record previously. Battelle sent NTP the Bulk Chemical Shipment Report dated June 22, 2004 verifying it had shipped samples of the 4 anthraquinone lots to BioReliance on June 1, 2004. This document also was provided by NTP to you in NTP's Response to the Request for Correction. BioReliance confirmed assignment of each test article aliquot number to the correct lot of anthraquinone. You were sent this document previously. The review of these records provided assurance that the samples were handled appropriately and in conformity with routine procedures."

In their responses outlined above, HHS affirmed that the samples were appropriately labeled and that Sample A07496, tested by BioReliance Corp., was an aliquot of the TR 494 test article. In the Genetic Toxicology section, TR 494 states (p246): "Sample A07496 (lot no. 5893) from Zeneca Fine Chemicals ... was from the lot used in the 2-year studies ..." and that this sample was tested in *Salmonella typhimurium* strains TA98, TA100 and TA1537. TR 494 clearly reports the mutagenicity testing results of Sample A07496 (p248): "Sample A07496, the compound used in the 2-year studies (99.8% pure), was negative in TA98, TA100, and TA1537, with and without 10% and 30% rat S9 at concentrations up to 10,000 µg/plate with both solvents (Table E3)."

*Based on the information provided in TR 494, in conjunction with HHS's responses to your prior Requests for Correction and Reconsideration concerning mutagenicity testing of Sample A07496, EPA concludes that there is no evidence of noncompliance with EPA IQGs for TR 494.*

## 2. Storage of TR 494 test article

During the December 9, 2005 meeting of the Board of Scientific Counselors Technical Subcommittee, Dr. Cynthia Smith mistakenly indicated that the 9,10-AQ sample that had been tested for mutagenicity had been taken from an archived sample stored "frozen under argon" when it had instead been taken from archived bulk material stored at room temperature (in an amber glass bottle). The CPC RFC asserts that "... the possibility of decomposition of biologically significant mutagenic impurities in the TR-494 test article over time confounds interpretation of a 2004 negative mutagenicity assay, even if the assay had been performed on an aliquot of the TR-494 test article."

HHS specifically addressed the issue of the 9,10-AQ sample storage and Dr. Smith's statement in their December 22, 2006 Response to your May 31, 2006 Request for Correction (as amended on July 13 and July 17) and in their September 22, 2008 Response to your January 5, 2007 Request for Reconsideration (as amended on March 1, 2007). Specifically, in their 2006 response, HHS agreed to address the misstatement by Dr. Smith by electronic and text erratum and indicated that storage in amber glass bottles at room temperature is the recommended storage conditions for 9,10-AQ. Also in the 2006 response, HHS addressed the issue of possible degradation of impurities. HHS indicated that: "The purity analyses described above and in Appendix J of TR494 were all conducted on aliquots of the anthraquinone test article lot no. 5893 stored at room temperature. Each of these analyses conducted

at different times over a 10-year period gave purity values for the anthraquinone test article lot no. 5893 that are in agreement and do not show evidence of degradation of the bulk test article”.

EPA concludes that the misstatement by Dr. Smith had no bearing on the scientific conclusions in TR 494. HHS appropriately corrected this misstatement by a published erratum. The test article was stored according to recommended storage conditions and purity analyses conducted over a ten-year time period showed no evidence of degradation. Importantly, the potential contribution of contaminants to the overall carcinogenicity findings in TR 494 was discussed in detail by the Board of Scientific Counselors Technical Subcommittee. EPA agrees with the conclusions presented by NTP (Dr. Irwin) at the December 9, 2005 Board of Scientific Counselors Technical Subcommittee meeting that “the low exposure levels, bioavailability, and relative mutagenicity make it unlikely that 9-nitroanthracene contributed significantly to the results of the carcinogenicity studies.” As such, the “possibility of decomposition” of mutagenic contaminants (specifically 9-nitroanthracene) in Sample A07496 prior to mutagenicity testing does not alter the overall conclusions regarding the carcinogenicity of 9,10-AQ as it is unlikely that the contaminants contributed significantly to the carcinogenic responses reported in TR 494.

In summary, TR 494 was conducted in compliance with Good Laboratory Practice (GLP) regulations as defined by the Food and Drug Administration (FDA), was subjected to quality assurance audits and received appropriate peer review. TR 494 clearly acknowledges the issue of potential contamination of the test article with 9-nitroanthracene and transparently states (p93): “Based on the information currently available, it is not possible to determine to what extent, if any, 9-nitroanthracene influenced the carcinogenic response in the 2-year studies.”

*Based on the information provided in TR 494, in conjunction with HHS’s responses to your prior Requests for Correction and Reconsideration concerning Dr. Smith’s misstatement and the potential for degradation of contaminants in the TR 494 test article, EPA concludes that there is no evidence of noncompliance with EPA IQGs for TR 494.*

B. There is no scientifically sound basis for concluding that non-mutagenic 9,10-AQ caused cancers in NTP TR 494

As mentioned above, TR 494 was conducted in compliance with Good Laboratory Practice (GLP) regulations as defined by the Food and Drug Administration (FDA), was subjected to quality assurance audits and received appropriate peer review.

The issue of contamination of the 9,10-AQ test article with 9-nitroanthracene was discussed by the Board of Scientific Counselors Technical Subcommittee and was transparently acknowledged in TR 494. In fact, TR 494 clearly states (p92): “The NTP was unable to confirm the bacterial mutagenicity of the anthraquinone used in the NTP studies described in this Technical Report.” The TR 494 peer reviewers were provided the mutagenicity testing results of the TR 494 test article and discussed the results in relation to the carcinogenic findings. They agreed that the carcinogenic results reported in TR 494 were valid.

EPA agrees with the conclusions in TR 494 regarding the carcinogenic activity of 9,10-AQ in male and female F344 rats and B6C3F1 mice. EPA also agrees with the following (p93) in TR 494: “Based on the information currently available, it is not possible to determine to what extent, if any, 9-nitroanthracene

influenced the carcinogenic response in the 2-year studies. The anthraquinone tested, greater than 99.8% pure, produced a carcinogenic response consistent with that observed with other anthraquinones. The biotransformation of anthraquinone to mutagenic metabolites with systemic concentrations at least five times greater than is possible for 9-nitroanthracene indicate that anthraquinone is potentially carcinogenic.”

The lack of bacterial mutagenicity does not equate to a lack of carcinogenicity *in vivo*. There are several potential modes of action for carcinogenic compounds, mutagenicity is only one. Neither NTP (in TR 494) nor EPA (in the 9,10-AQ PPRTV) asserts that 9,10-AQ induced tumors in TR 494 through a mutagenic mode of action.

*EPA concludes that there is no evidence of noncompliance with EPA IQGs for TR 494 or the 9,10-AQ PPRTV.*

### C. There is no scientifically sound basis for considering non-mutagenic 9,10-AQ likely to be carcinogenic to humans

In determining the cancer Weight of Evidence (WOE) descriptor in the 9,10-AQ PPRTV, EPA reviewed all available information from epidemiological, toxicological and mode of action studies in accordance with EPA’s *Guidelines for Carcinogen Risk Assessment*. The 9,10-AQ PPRTV details the information that the descriptor “likely to be carcinogenic to humans” is based on, noting the strengths and weaknesses of the evidence. The information considered in determining the cancer WOE descriptor for 9,10-AQ included information from all lines of evidence and was not “solely from” TR 494 as asserted in the CPC RFC.

The 9,10-AQ PPRTV does not determine a mode of action for 9,10-AQ and clearly states (p26): “The majority of data on 9,10-anthraquinone indicate that 9,10-anthraquinone is not mutagenic.”

The evaluation of the carcinogenicity evidence and the conclusion that 9,10-AQ is likely to be carcinogenic to humans in the 9,10-AQ PPRTV was reviewed by independent scientific experts (external peer reviewers) following applicable EPA peer review guidelines. No new scientific information was provided in the CPC RFC that would alter the conclusion in the 9,10-AQ PPRTV that 9,10-AQ is appropriately classified as likely to be carcinogenic to humans.

*EPA concludes that there is no evidence of noncompliance with EPA IQGs for the 9,10-AQ PPRTV.*

### D. EPA’s screening levels for 9,10-AQ do not reflect sound and objective scientific practices

The CPC RFC asserts that the 9,10-AQ PPRTV does not reflect “sound and objective scientific practices” because the assessment relies on TR 494 in deriving toxicity values. The CPC RFC specifically requests that the 9,10-AQ PPRTV be withdrawn and that 9,10-AQ be removed from the RSL Tables. The information for 9,10-AQ in the RSL Tables was taken directly from the 9,10-AQ PPRTV. As such, these two issues are interrelated and will be discussed together below.

#### 1. The 9,10-AQ PPRTV should be withdrawn

#### 2. 9,10-AQ should be removed from the RSL Tables

The subchronic and chronic provisional screening Reference Doses (p-RfDs) derived in the 9,10-AQ PPRTV are based on noncancer adverse effects, not carcinogenic (or mutagenic) effects. The issues raised in the CPC RFC concerning the mutagenicity/carcinogenicity findings in TR 494 are not relevant to



the derivation of noncancer toxicity values in the 9,10-AQ PPRTV. There is no new information provided in the CPC RFC that is relevant to the noncancer subchronic or chronic screening p-RfDs derived in the 9,10-AQ PPRTV.

The 9,10-AQ PPRTV was developed following all applicable EPA guidelines. Following public release of the 9,10-AQ PPRTV, the 9,10-AQ toxicity values derived in the PPRTV were included in the RSL Tables.

EPA acknowledged the issue of 9-nitroanthracene (9-NA) contamination of the 9,10-AQ test article utilized in TR 494 within the PPRTV and summarized the NTP Board of Scientific Counselors Technical Review Subcommittee findings regarding the issue (see pp 8, 25 & 26 of the 9,10-AQ PPRTV). This information was reviewed by independent scientific experts (external peer reviewers) following all applicable EPA peer review guidelines.

In response to this RFC, EPA conducted an additional evaluation of TR 494 using standardized study quality evaluation criteria (see Attachment 2). This evaluation resulted in a determination of “High Confidence” for TR 494. Based on this study quality evaluation, EPA again concludes that there is no evidence of noncompliance with EPA’s IQGs for TR 494.

*EPA concludes that there is no evidence of noncompliance with EPA’s IQGs for the 9,10-AQ PPRTV or the 9,10-AQ toxicity values in the RSL Tables.*

## **Conclusion**

EPA, after careful review of the RFC submitted by CPC, has concluded that the underlying information and conclusions presented in *Provisional Peer Reviewed Toxicity Values for 9,10-Anthraquinone (CASRN 84-65-1)* and in the RSL Tables are consistent with EPA’s IQGs.

**Attachment 2**

**Study Quality Evaluation of *NTP Technical Report on the Toxicology and Carcinogenesis Studies of Anthraquinone (CAS No. 84-65-1) in R344/N Rats and B6C3F1 Mice (Feed Studies) ("TR 494")***

**September 2018**

National Center for Environmental Assessment  
Office of Research and Development  
U.S. Environmental Protection Agency

## Study Quality Evaluation of TR 494

The Chemical Products Corporation (CPC) Request for Correction (RFC) asserts that *NTP Technical Report on the Toxicology and Carcinogenesis Studies of Anthraquinone (CAS No. 84-65-1) in R344/N Rats and B6C3F1 Mice (Feed Studies)* (herein referred to as “TR 494”) does not represent “sound science.” In response to this RFC, EPA conducted a study quality evaluation of TR 494 to assess risk of bias and sensitivity. The results of the study quality evaluation of TR 494 are shown in Figure 2-1.


Key issues during this evaluation were potential bias (factors that affect the magnitude or direction of an effect) and insensitivity (factors that limit the ability of a study to detect a true effect). The study quality evaluation of TR 494 was conducted for the following study domains: reporting quality, selection or performance bias, confounding/variable control, reporting or attrition bias, exposure methods sensitivity, and outcome measures and results display (see [Table 2-1](#)).

All study domains were judged to be *Good* with the exception of “Characterization of the exposure to the compound of interest” which was judged to be *Adequate*. This domain was judged to be *Adequate* due to uncertainty related to the impact, if any, of the impurities in the TR 494 test compound. The percent purity of the test compound was well documented, the impurities detected were reported and the issue of contamination was discussed within TR 494 and as part of the TR 494 peer review process. EPA agrees with the conclusion of NTP (Dr. Irwin) (TR 494; p18) that: “The low exposure levels, bioavailability, and relative mutagenicity make it unlikely that 9-nitroanthracene contributed significantly to the results of the carcinogenicity studies.”

The study quality evaluation of TR 494 results in an overall study quality classification of “High Confidence” (see “Study Quality Evaluation Methodology” below).

EPA concludes that TR 494 is an appropriate study for use in the derivation of toxicity values for 9,10-AQ.

**Figure 2-1. Study quality evaluation results for TR 494**



### Study Quality Evaluation Methodology

The study quality evaluation of TR 494 was conducted on the following domains: reporting quality, selection or performance bias, confounding/variable control, reporting or attrition bias, exposure methods sensitivity, and outcome measures and results display (see Table 2-1).

For each study domain, a judgment of *Good*, *Adequate*, *Deficient*, *Not Reported* or *Critically deficient* was made. These five categories were applied to each evaluation domain as follows:

- *Good* represents a judgment that the study was conducted appropriately in relation to the evaluation domain, and any minor deficiencies that are noted would not be expected to influence the study results.
- *Adequate* indicates a judgment that there are methodological limitations relating to the evaluation domain, but that those limitations are not likely to be severe or to have a notable impact on the results.

- *Deficient* denotes identified biases or deficiencies that are interpreted as likely to have had a notable impact on the results or that prevent reliable interpretation of the study findings.
- *Not reported* indicates that the information necessary to evaluate the domain question was not available in the study. Generally, this term carries the same functional interpretation as *Deficient* for the purposes of the study confidence classification (described below).
- *Critically deficient* reflects a judgment that the study conduct relating to the evaluation domain question introduced a serious flaw that is the primary driver of any observed effect(s) or makes the study uninterpretable.

**Table 2-1. Domains of study quality evaluation for TR 494**

Evaluation type	Domain – Core question	Prompting questions	Basic Considerations
Reporting Quality	<p><b>Reporting Quality</b> – Does the study report information for evaluating the design and conduct of the study for the endpoint(s)/outcome(s) of interest?</p> <p><i>Notes:</i></p> <p><i>This domain is limited to reporting. Other aspects of the exposure methods, experimental design, and endpoint evaluation methods are evaluated using the domains related to risk of bias and study sensitivity.</i></p>	<p>Does the study report the following?</p> <ul style="list-style-type: none"> <li>• <b><u>Critical information</u></b> necessary to perform study evaluation: <ul style="list-style-type: none"> <li>○ Species; test article name; levels and duration of exposure; route (e.g., oral; inhalation); qualitative or quantitative results for at least one endpoint of interest</li> </ul> </li> <li>• <b><u>Important information</u></b> for evaluating the study methods: <ul style="list-style-type: none"> <li>○ Test animal: strain, sex, source, and general husbandry procedures</li> <li>○ Exposure methods: source, purity, method of administration</li> <li>○ Experimental design: frequency of exposure, animal age and lifestage during exposure and at endpoint/outcome evaluation</li> <li>○ Endpoint evaluation methods: assays or procedures used to measure the endpoints/outcomes of interest</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• <i>Good:</i> All <b><u>critical and important information</u></b> is reported or inferable for the endpoints/outcomes of interest.</li> <li>• <i>Adequate:</i> All <b><u>critical information</u></b> is reported but some <b><u>important information</u></b> is missing. However, the missing information is not expected to significantly impact the study evaluation.</li> <li>• <i>Deficient:</i> All <b><u>critical information</u></b> is reported but <b><u>important information</u></b> is missing that is expected to significantly reduce the ability to evaluate the study.</li> <li>• <i>Critically Deficient:</i> Study report is missing any pieces of <b><u>critical information</u></b>.</li> </ul>
Risk of Bias Selection and performance bias	<p><b>Allocation</b> – Were animals assigned to experimental groups using a method that minimizes selection bias?</p>	<p>For each study:</p> <ul style="list-style-type: none"> <li>• Did each animal or litter have an equal chance of being assigned to any experimental group (i.e., random allocation)?</li> <li>• Is the allocation method described?</li> <li>• Aside from randomization, were any steps taken to</li> </ul>	<p>A judgment and rationale for this domain should be given for each cohort or experiment in the study.</p> <ul style="list-style-type: none"> <li>• <i>Good:</i> Experimental groups were randomized and any specific randomization procedure was described or inferable (e.g., computer-generated scheme). [Note that normalization is not the same as</li> </ul>

Evaluation type	Domain – Core question	Prompting questions	Basic Considerations
		<p>balance variables across experimental groups during allocation?</p>	<p>randomization (see response for ‘Adequate’).]</p> <ul style="list-style-type: none"> <li>• <i>Adequate</i>: Authors report that groups were randomized but do not describe the specific procedure used (e.g., “animals were randomized”). Alternatively, authors used a non-random method to control for important modifying factors across experimental groups (e.g., body weight normalization).</li> <li>• <i>Not Reported</i> (interpreted as <i>Deficient</i>): No indication of randomization of groups or other methods (e.g., normalization) to control for important modifying factors across experimental groups.</li> <li>• <i>Critically Deficient</i>: Bias in the animal allocations was reported or inferable.</li> </ul>
	<p><b>Observational bias/Blinding</b> – Did the study implement measures to reduce observational bias?</p>	<p>For each endpoint/outcome or grouping of endpoints/outcomes in a study:</p> <ul style="list-style-type: none"> <li>• Does the study report blinding or other methods/procedures for reducing observational bias?</li> <li>• If not, did the study use a design or approach for which such procedures can be inferred?</li> <li>• What is the expected impact of failure to implement (or report implementation) of these methods/procedures on results?</li> </ul>	<p>A judgment and rationale for this domain should be given for each endpoint/outcome or group of endpoints/outcomes investigated in the study.</p> <ul style="list-style-type: none"> <li>• <i>Good</i>: Measures to reduce observational bias were described (e.g. blinding to conceal treatment groups during endpoint evaluation; consensus-based evaluations of histopathology lesions<sup>1</sup>).</li> <li>• <i>Adequate</i>: Methods for reducing observational bias (e.g., blinding) can be inferred or were reported but described incompletely.</li> <li>• <i>Not Reported</i>: Measures to reduce observational bias were not described. <ul style="list-style-type: none"> <li>○ (interpreted as <i>Adequate</i>) The potential concern for bias was</li> </ul> </li> </ul>

<sup>1</sup> For non-targeted or screening-level histopathology outcomes often used in guideline studies, blinding during the initial evaluation of tissues is generally not recommended as masked evaluation can make “the task of separating treatment-related changes from normal variation more difficult” and “there is concern that masked review during the initial evaluation may result in missing subtle lesions.” Generally, blinded evaluations are recommended for targeted secondary review of specific tissues or in instances when there is a pre-defined set of outcomes that is known or predicted to occur (Crissman et al., 2004). Crissman et al. (2004). Best practices guideline: toxicologic histopathology. Toxicol Pathol. Jan-Feb;32(1):126-31.

Evaluation type	Domain – Core question	Prompting questions	Basic Considerations
			<p>mitigated based on use of automated/computer driven systems, standard laboratory kits, relatively simple, objective measures (e.g., body or tissue weight), or screening-level evaluations of histopathology.</p> <ul style="list-style-type: none"> <li>○ (interpreted as <i>Deficient</i>) The potential impact on the results is major (e.g., outcome measures are highly subjective).</li> <li>● <i>Critically Deficient</i>: Strong evidence for observational bias that could have impacted results</li> </ul>
<p style="text-align: center;">Confounding/ variable control</p>	<p><b>Confounding –</b> Are variables with the potential to confound or modify results controlled for and consistent across all experimental groups?</p>	<p>For each study:</p> <ul style="list-style-type: none"> <li>● Are there differences across the treatment groups (e.g., co-exposures, vehicle, diet, palatability, husbandry, health status, etc.) that could bias the results?</li> <li>● If differences are identified, to what extent are they expected to impact the results?</li> </ul>	<p>A judgment and rationale for this domain should be given for each cohort or experiment in the study, noting when the potential for confounding is restricted to specific endpoints/outcomes.</p> <ul style="list-style-type: none"> <li>● <i>Good</i>: Outside of the exposure of interest, variables that are likely to confound or modify results appear to be controlled for and consistent across experimental groups.</li> <li>● <i>Adequate</i>: Some concern that variables that were likely to confound or modify results were uncontrolled or inconsistent across groups, but are expected to have a minimal impact on the results.</li> <li>● <i>Deficient</i>: Notable concern that potentially confounding variables were uncontrolled or inconsistent across groups, and are expected to substantially impact the results.</li> <li>● <i>Critically deficient</i>: Confounding variables were presumed to be uncontrolled or inconsistent across groups, and are expected to be a primary driver of the results.</li> </ul>
<p style="text-align: center;">Reporting and attrition bias</p>	<p><b>Selective reporting and attrition –</b> Did the study report results for all</p>	<p>For each study:</p>	<p>A judgment and rationale for this domain should be given for each cohort or experiment in the study.</p> <ul style="list-style-type: none"> <li>● <i>Good</i>: Quantitative or qualitative results were reported for all prespecified outcomes (explicitly</li> </ul>



Evaluation type	Domain – Core question	Prompting questions	Basic Considerations
	<p>prespecified outcomes and tested animals?</p> <p><i>Note:</i></p> <p><i>This domain does <b>not</b> consider the appropriateness of the analysis/results presentation. This aspect of study quality is evaluated in another domain.</i></p>	<p><i>Selective reporting bias:</i></p> <ul style="list-style-type: none"> <li>• Are all results presented for endpoints/outcomes described in the methods (see note)?</li> </ul> <p><i>Attrition bias:</i></p> <ul style="list-style-type: none"> <li>• Are all animals accounted for in the results?</li> <li>• If there are discrepancies, do authors provide an explanation (e.g., death or unscheduled sacrifice during the study)?</li> <li>• If unexplained results omissions and/or attrition are identified, what is the expected impact on the interpretation of the results?</li> </ul>	<p>stated or inferred), exposure groups and evaluation timepoints. Data not reported in the primary article is available from supplemental material. If results omissions or animal attrition are identified, the authors provide an explanation and these are not expected to impact the interpretation of the results.</p> <ul style="list-style-type: none"> <li>• <i>Adequate:</i> Quantitative or qualitative results are reported for most prespecified outcomes (explicitly stated or inferred), exposure groups and evaluation timepoints. Omissions and/or attrition are not explained, but are not expected to significantly impact the interpretation of the results.</li> <li>• <i>Deficient:</i> Quantitative or qualitative results are missing for many prespecified outcomes (explicitly stated or inferred), exposure groups and evaluation timepoints and/or high animal attrition; omissions and/or attrition are not explained and may significantly impact the interpretation of the results.</li> <li>• <i>Critically Deficient:</i> Extensive results omission and/or animal attrition are identified and prevents comparisons of results across treatment groups.</li> </ul>
Sensitivity	<p><b>Chemical administration and characterization –</b></p> <p>Did the study adequately characterize exposure to the chemical of interest and the exposure administration methods?</p>	<p>For each study:</p> <ul style="list-style-type: none"> <li>• Does the study report the source and purity and/or composition (e.g., identity and percent distribution of different isomers) of the chemical? If not, can the purity and/or composition be obtained from the supplier (e.g., as reported on the website)</li> <li>• Was independent analytical verification of the test article</li> </ul>	<p>A judgment and rationale for this domain should be given for each cohort or experiment in the study.</p> <ul style="list-style-type: none"> <li>• <i>Good:</i> Chemical administration and characterization is complete (i.e., source, purity, and analytical verification of the test article are provided). There are no concerns about the composition, stability, or purity of the administered chemical, or the specific methods of administration. For inhalation studies, chemical concentrations in the exposure chambers are verified using reliable analytical methods.</li> <li>• <i>Adequate:</i> Some uncertainties in the chemical administration and characterization are identified but</li> </ul>

Evaluation type	Domain – Core question	Prompting questions	Basic Considerations
		<p>purity and composition performed?</p> <ul style="list-style-type: none"> <li>• Did the authors take steps to ensure the reported exposure levels were accurate? <ul style="list-style-type: none"> <li>○ For inhalation studies: were target concentrations confirmed using reliable analytical measurements in chamber air?</li> <li>○ For oral studies: if necessary based on consideration of chemical-specific knowledge (e.g., instability in solution; volatility) and/or exposure design (e.g., the frequency and duration of exposure), were chemical concentrations in the dosing solutions or diet analytically confirmed?</li> </ul> </li> <li>• Are there concerns about the methods used to administer the chemical (e.g., inhalation chamber type, gavage volume, etc.)?</li> </ul>	<p>these are expected to have minimal impact on interpretation of the results (e.g., source and vendor- reported purity are presented, but not independently verified; purity of the test article is sub-optimal but not concerning; For inhalation studies, actual exposure concentrations are missing or verified with less reliable methods).</p> <ul style="list-style-type: none"> <li>• <i>Deficient:</i> Uncertainties in the exposure characterization are identified and expected to substantially impact the results (e.g., source of the test article is not reported; levels of impurities are substantial or concerning; deficient administration methods, such as use of static inhalation chambers or a gavage volume considered too large for the species and/or lifestage at exposure).</li> <li>• <i>Critically Deficient:</i> Uncertainties in the exposure characterization are identified and there is reasonable certainty that the results are largely attributable to factors other than exposure to the chemical of interest (e.g., identified impurities are expected to be a primary driver of the results).</li> </ul>

		<p><b>Exposure timing, frequency and duration –</b></p> <p>Was the was the timing, frequency, and duration of exposure sensitive for the endpoint(s)/outcome(s) of interest?</p>	<p>For each endpoint/outcome or grouping of endpoints/outcomes in a study:</p> <ul style="list-style-type: none"> <li>• Does the exposure period include the critical window of sensitivity?</li> <li>• Was the duration and frequency of exposure sensitive for detecting the endpoint of interest?</li> </ul>	<p>A judgment and rationale for this domain should be given for each endpoint/outcome or group of endpoints/outcomes investigated in the study.</p> <ul style="list-style-type: none"> <li>• <i>Good</i>: The duration and frequency of the exposure was sensitive and the exposure included the critical window of sensitivity (if known).</li> <li>• <i>Adequate</i>: The duration and frequency of the exposure was sensitive and the exposure covered most of the critical window of sensitivity (if known).</li> <li>• <i>Deficient</i>: The duration and/or frequency of the exposure is not sensitive and did not include the majority of the critical window of sensitivity (if known). These limitations are expected to bias the results towards the null.</li> <li>• <i>Critically deficient</i>: The exposure design was not sensitive and is expected to strongly bias the results towards the null. The rationale should indicate the specific concern(s).</li> </ul>
	<p style="writing-mode: vertical-rl; transform: rotate(180deg);"><b>Outcome measures and results display</b></p>	<p><b>Endpoint sensitivity and specificity –</b></p> <p>Are the procedures sensitive and specific for evaluating the endpoint(s)/outcome(s) of interest?</p> <p><i>Note:</i></p> <p><i>Sample size alone is not a reason to conclude an individual study is critically deficient.</i></p>	<p>For each endpoint/outcome or grouping of endpoints/outcomes in a study:</p> <ul style="list-style-type: none"> <li>• Are there concerns regarding the specificity and validity of the protocols?</li> <li>• Are there serious concerns regarding the sample size (see note)?</li> <li>• Are there concerns regarding the timing of the endpoint assessment?</li> </ul>	<p>A judgment and rationale for this domain should be given for each endpoint/outcome or group of endpoints/outcomes investigated in the study.</p> <p>Examples of potential concerns include:</p> <ul style="list-style-type: none"> <li>• Selection of protocols that are insensitive or non-specific for the endpoint of interest</li> <li>• Use of unreliable methods to assess the outcome</li> <li>• Assessment of endpoints at inappropriate or insensitive ages, or without addressing known endpoint variation (e.g., due to circadian rhythms, estrous cyclicity, etc.).</li> <li>• Decreased specificity or sensitivity of the response due to the timing of endpoint evaluation, as compared to exposure (e.g., short-acting depressant or irritant effects of chemicals; insensitivity due to</li> </ul>

Evaluation type	Domain – Core question	Prompting questions	Basic Considerations
	<p><b>Results Presentation –</b> Are the results presented in a way that makes the data usable and transparent?</p>	<p>For each endpoint/outcome or grouping of endpoints/outcomes in a study:</p> <ul style="list-style-type: none"> <li>• Does the level of detail allow for an informed interpretation of the results?</li> <li>• Are the data analyzed, compared, or presented in a way that is inappropriate or misleading?</li> </ul>	<p>prolonged period of non-exposure prior to testing).</p> <p>A judgment and rationale for this domain should be given for each endpoint/outcome or group of endpoints/outcomes investigated in the study.</p> <p>Examples of potential concerns include:</p> <ul style="list-style-type: none"> <li>• Non-preferred presentation, such as developmental toxicity data averaged across pups in a treatment group, when litter responses are more appropriate</li> <li>• Failing to present quantitative results</li> <li>• Pooling data when responses are known or expected to differ substantially (e.g., across sexes or ages)</li> <li>• Failing to report on or address overt toxicity when exposure levels are known or expected to be highly toxic</li> <li>• Lack of full presentation of the data (e.g., presentation of mean without variance data; concurrent control data are not presented)</li> </ul>

Once the evaluation domains were considered, an overall study confidence classification for TR 494 was made. This classification was based on the judgments across the evaluation domains and included consideration of the likely impact of the noted deficiencies in bias and sensitivity, or inadequate reporting, on the results. The overall study confidence classifications are defined as follows:

- *High confidence*: No notable deficiencies or concerns were identified; the potential for bias is unlikely or minimal, and the study used sensitive methodologies. In general, although classifications are not decided by “scoring,” *High confidence* studies would reflect judgments of *Good* across all or most evaluation domains.
- *Medium confidence*: Possible deficiencies or concerns were noted, but the limitations are unlikely to be of a notable degree. Generally, *Medium confidence* studies will include *Adequate* or *Good* judgments across most domains, with the impact of any identified limitation not being

judged as severe.

- *Low confidence*: Deficiencies or concerns were noted, and the potential for substantive bias or inadequate sensitivity could have a significant impact on the study results or their interpretation. Typically, *Low confidence* studies would have a *Deficient* evaluation for one or more domains (unless the impact of the limitations on the results is judged as unlikely to be severe).

- *Uninformative*: Serious flaw(s) make the study results unusable for informing hazard identification. Studies with *Critically deficient* judgements in any evaluation domain will almost always be classified as *Uninformative* (see explanation above). Studies with multiple *Deficient* judgments across domains may also be considered *Uninformative*, particularly when there is a robust database of studies on the outcome(s) of interest or when the impact of the limitations is viewed as severe.

## RFR Attachment 3

Response by NIEHS/NTP Deputy Director Samuel H. Wilson  
to CPC's March 27, 2003 RFR

September 8, 2003 letter to CPC



September 8, 2003

**National Institutes of Health  
National Institute of  
Environmental Health Sciences  
P.O. Box 12233  
Research Triangle Park, N.C. 27709  
Website: [www.niehs.nih.gov](http://www.niehs.nih.gov)**

Mr. Jerry A. Cook  
Technical Director  
Chemical Products Corporation  
Cartersville, Georgia 30120

Re: Request for Reconsideration submitted March 27, 2003

Dear Mr. Cook:

On behalf of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), I am responding to your March 27, 2002, Request for Reconsideration submitted for the Chemical Products Corporation (CPC) under the NIH's "Guidelines for Ensuring the Quality of Information Disseminated to the Public" (NIH Guidelines). Your Reconsideration Request appealed the NIH's March 19, 2003, decision regarding the CPC's November 15, 2003, Request for Correction contained in the Abstract for Draft National Toxicology Program (NTP) Technical Report # TR-494. A summary of the background information on the study that culminated in draft TR-494, the process I used to consider the appeal, and my conclusions are provided as follows:

*Background:* The NTP conducted a 2-year carcinogenicity study in rodents on a batch of anthraquinone obtained commercially that was shown to be 99.9% pure; results of this study eventually led to a draft report termed TR-494. Once it was peer reviewed, the abstract of draft TR-494 was posted on the NTP website. On July 25, 2000, you sent a letter to Dr. Kenneth Olden, Director of the NTP, stating that the sample of anthraquinone tested contained a 0.1% contamination by 9-nitroanthracene, a mutagenic compound, and noting that the presence of this contaminant called the study interpretations into question. The NTP followed up on your letter, confirming that a contaminant in the anthraquinone sample at about the 0.1% level was indeed 9-nitroanthracene. The NTP then initiated the process, in September 2000, to assess the metabolism of the parent compound, anthraquinone, in rodents, and to assess the relative mutagenicity in an Ames test of anthraquinone, its two major urinary metabolites, the contaminant 9-nitroanthracene, and two isomers of 9-nitroanthracene. You subsequently filed an Information Quality Request for Correction on November 15, 2002, asking that the abstract be immediately removed from the NTP's website in view of errors or misleading statements in the material presented. On March 19, 2003, NIH sent you a response to your Request for Correction stating that additional information would be incorporated into the NTP web site to clarify the material in the abstract of draft TR-494 and informing you about ongoing follow-up studies of

anthraquinone. The NTP amended the abstract of draft TR-494 on April 1, 2003, on its website to include reference to the 9-nitroanthracene contaminant, and the NTP also made mention of ongoing studies to resolve whether or not this contaminant might have affected the 2-year study results. On March 27, 2003, you submitted a Request for Reconsideration to NIH.

*Process:* In the course of my review, I have reviewed the HHS and NIH Guidelines for Ensuring the Quality of Information Disseminated to the Public, read draft TR-494, and read Chemical Products Corporation's letters and the NTP's responses to those letters. I have consulted with NIH and HHS staff familiar with the Information Quality process. I also have reviewed data and ongoing tests with the staff of NIEHS' Environmental Toxicology Program who were responsible for the NTP studies and draft report. I have been assisted in these efforts by staff from the NIEHS Office of Policy, Planning and Evaluation.


*Conclusions:* Following the process outlined above and after careful review of the information that I have described, I have reached the following conclusions:

1. The sample of anthraquinone used in the NTP 2-year study was contaminated with 9-nitroanthracene at a level of about 0.1%.
2. The presence of this contaminant raises doubt as to the effect(s) of anthraquinone itself, or its metabolites, and confounds interpretation of the NTP studies referenced in draft TR-494. In addition, in view of imprecise statements in the text presented on the website, this abstract needs to have greater specificity than it presently has.
3. The abstract of draft TR-494 will immediately be removed from the NTP website.

Further studies are underway on the metabolism of anthraquinone in rodents and on the relative mutagenic potency of this compound, its major metabolites, the contaminant 9-nitroanthracene, and two isomers of 9-nitroanthracene. Additional information from this work will eventually be incorporated into a revised abstract and technical report which will be submitted for peer review and subsequent publication.

I appreciate your comments and hope that the actions that I have taken address your concerns.

Sincerely,



Samuel H. Wilson, M.D.  
Deputy Director

cc: Mary Wolfe, Ph.D.  
Director, NTP Liaison and Scientific Review Office